EP3227661A1 - Cell processing using magnetic particles - Google Patents
Cell processing using magnetic particlesInfo
- Publication number
- EP3227661A1 EP3227661A1 EP15866159.5A EP15866159A EP3227661A1 EP 3227661 A1 EP3227661 A1 EP 3227661A1 EP 15866159 A EP15866159 A EP 15866159A EP 3227661 A1 EP3227661 A1 EP 3227661A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sperm
- magnetic particles
- cells
- composition
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006249 magnetic particle Substances 0.000 title claims abstract description 183
- 238000012545 processing Methods 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 188
- 239000000203 mixture Substances 0.000 claims abstract description 160
- 239000000872 buffer Substances 0.000 claims description 16
- 241000283690 Bos taurus Species 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 230000003300 photodamaging effect Effects 0.000 claims description 4
- 241000283073 Equus caballus Species 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims 3
- 230000003000 nontoxic effect Effects 0.000 claims 3
- 230000009027 insemination Effects 0.000 abstract description 27
- 241001465754 Metazoa Species 0.000 abstract description 10
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 203
- 239000002245 particle Substances 0.000 description 117
- 239000000523 sample Substances 0.000 description 91
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 57
- 239000000975 dye Substances 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 42
- 102000004169 proteins and genes Human genes 0.000 description 40
- 239000012192 staining solution Substances 0.000 description 36
- 230000004899 motility Effects 0.000 description 35
- 238000010186 staining Methods 0.000 description 35
- 210000003850 cellular structure Anatomy 0.000 description 34
- 230000035899 viability Effects 0.000 description 34
- 239000012530 fluid Substances 0.000 description 33
- 230000008569 process Effects 0.000 description 31
- -1 NT A Chemical compound 0.000 description 28
- 210000000582 semen Anatomy 0.000 description 28
- 239000002210 silicon-based material Substances 0.000 description 28
- 239000000654 additive Substances 0.000 description 26
- 230000001010 compromised effect Effects 0.000 description 26
- 210000002593 Y chromosome Anatomy 0.000 description 25
- 229910052742 iron Inorganic materials 0.000 description 24
- 239000012528 membrane Substances 0.000 description 23
- 239000000758 substrate Substances 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 229910001868 water Inorganic materials 0.000 description 20
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 19
- 239000003242 anti bacterial agent Substances 0.000 description 19
- 239000012472 biological sample Substances 0.000 description 19
- 210000001766 X chromosome Anatomy 0.000 description 18
- 238000003860 storage Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000003963 antioxidant agent Substances 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 16
- 239000002577 cryoprotective agent Substances 0.000 description 16
- 241000894007 species Species 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000004720 fertilization Effects 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000007983 Tris buffer Substances 0.000 description 14
- 229940088710 antibiotic agent Drugs 0.000 description 14
- 238000005138 cryopreservation Methods 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 239000010902 straw Substances 0.000 description 14
- 235000020942 vitamer Nutrition 0.000 description 14
- 239000011608 vitamer Substances 0.000 description 14
- 102000002322 Egg Proteins Human genes 0.000 description 13
- 108010000912 Egg Proteins Proteins 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 13
- 230000000996 additive effect Effects 0.000 description 13
- 239000011162 core material Substances 0.000 description 13
- 210000002969 egg yolk Anatomy 0.000 description 13
- 235000013345 egg yolk Nutrition 0.000 description 13
- 235000013601 eggs Nutrition 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- 244000309464 bull Species 0.000 description 12
- 230000035558 fertility Effects 0.000 description 12
- 235000013336 milk Nutrition 0.000 description 12
- 239000008267 milk Substances 0.000 description 12
- 210000004080 milk Anatomy 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000011554 ferrofluid Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 229940098773 bovine serum albumin Drugs 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 239000003102 growth factor Substances 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 238000010791 quenching Methods 0.000 description 9
- 230000000171 quenching effect Effects 0.000 description 9
- 230000035882 stress Effects 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 8
- 239000004606 Fillers/Extenders Substances 0.000 description 8
- 108010073771 Soybean Proteins Proteins 0.000 description 8
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000007710 freezing Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229940001941 soy protein Drugs 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000989 food dye Substances 0.000 description 7
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 7
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000007987 MES buffer Substances 0.000 description 6
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 6
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229910000077 silane Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000010257 thawing Methods 0.000 description 6
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 235000019136 lipoic acid Nutrition 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 230000008832 photodamage Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 229960002663 thioctic acid Drugs 0.000 description 5
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000000608 laser ablation Methods 0.000 description 4
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 4
- 229960005287 lincomycin Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002122 magnetic nanoparticle Substances 0.000 description 4
- 229940049920 malate Drugs 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- XJLTZAGUXSAJCZ-UHFFFAOYSA-N methyl 3-trimethoxysilylpropanoate Chemical compound COC(=O)CC[Si](OC)(OC)OC XJLTZAGUXSAJCZ-UHFFFAOYSA-N 0.000 description 4
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- 229960001790 sodium citrate Drugs 0.000 description 4
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 229960000268 spectinomycin Drugs 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 4
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 108010063907 Glutathione Reductase Proteins 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 108010046016 Peanut Agglutinin Proteins 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 229930003779 Vitamin B12 Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 229930003448 Vitamin K Natural products 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001343 alkyl silanes Chemical class 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 3
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 3
- 235000006279 cobamamide Nutrition 0.000 description 3
- 239000011789 cobamamide Substances 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 244000309465 heifer Species 0.000 description 3
- 235000004867 hydroxocobalamin Nutrition 0.000 description 3
- 239000011704 hydroxocobalamin Substances 0.000 description 3
- 229960001103 hydroxocobalamin Drugs 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 3
- 159000000014 iron salts Chemical class 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 229910044991 metal oxide Inorganic materials 0.000 description 3
- 150000004706 metal oxides Chemical class 0.000 description 3
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 3
- 235000007672 methylcobalamin Nutrition 0.000 description 3
- 239000011585 methylcobalamin Substances 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 210000000287 oocyte Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000005502 peroxidation Methods 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000003765 sex chromosome Anatomy 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 230000008010 sperm capacitation Effects 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- 229930003802 tocotrienol Natural products 0.000 description 3
- 239000011731 tocotrienol Substances 0.000 description 3
- 229940068778 tocotrienols Drugs 0.000 description 3
- 235000019148 tocotrienols Nutrition 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 235000019163 vitamin B12 Nutrition 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000019168 vitamin K Nutrition 0.000 description 3
- 239000011712 vitamin K Substances 0.000 description 3
- 150000003721 vitamin K derivatives Chemical class 0.000 description 3
- 229940046010 vitamin k Drugs 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- KRGPXXHMOXVMMM-CIUDSAMLSA-N (S,S,S)-nicotianamine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC[NH2+][C@H](C([O-])=O)CC[NH+]1CC[C@H]1C([O-])=O KRGPXXHMOXVMMM-CIUDSAMLSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 241000157855 Cinchona Species 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010093965 Polymyxin B Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 239000007994 TES buffer Substances 0.000 description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
- 229930194936 Tylosin Natural products 0.000 description 2
- 239000004182 Tylosin Substances 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- ONXOKWFYBIQOFQ-VSXSCALHSA-N ac1l4s0d Chemical compound OS(O)(=O)=O.O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O.O[C@@H]1[C@H](O)[C@@H](O)[C@@H](SC)O[C@@H]1[C@@H]([C@@H](C)O)NC(=O)[C@H]1N(C)C[C@H](C(C)C)C1 ONXOKWFYBIQOFQ-VSXSCALHSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960001489 deferasirox Drugs 0.000 description 2
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 2
- 229960000958 deferoxamine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 2
- 229960001051 dimercaprol Drugs 0.000 description 2
- BTVWZWFKMIUSGS-UHFFFAOYSA-N dimethylethyleneglycol Natural products CC(C)(O)CO BTVWZWFKMIUSGS-UHFFFAOYSA-N 0.000 description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
- JGOICJFFICGNEJ-UHFFFAOYSA-M disodium;3-[dihydroxy(oxido)silyl]propanoate Chemical compound [Na+].[Na+].O[Si](O)([O-])CCC([O-])=O JGOICJFFICGNEJ-UHFFFAOYSA-M 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 150000002211 flavins Chemical class 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- UCMFXAIFSBSDAQ-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O.CCCCCC(N)=O UCMFXAIFSBSDAQ-UHFFFAOYSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 150000003893 lactate salts Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 2
- 239000002159 nanocrystal Substances 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- KRGPXXHMOXVMMM-UHFFFAOYSA-N nicotianamine Natural products OC(=O)C(N)CCNC(C(O)=O)CCN1CCC1C(O)=O KRGPXXHMOXVMMM-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000001706 oxygenating effect Effects 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920000024 polymyxin B Polymers 0.000 description 2
- 229960005266 polymyxin b Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 125000003410 quininyl group Chemical group 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 239000011833 salt mixture Substances 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 230000019100 sperm motility Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 2
- 229960004659 ticarcillin Drugs 0.000 description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 2
- 229960004059 tylosin Drugs 0.000 description 2
- 235000019375 tylosin Nutrition 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 229910000859 α-Fe Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- OWMYPHUUGJUUBB-UHFFFAOYSA-N (acetyloxy-hexadecyl-methylsilyl) acetate Chemical compound CCCCCCCCCCCCCCCC[Si](C)(OC(C)=O)OC(C)=O OWMYPHUUGJUUBB-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- DCQBZYNUSLHVJC-UHFFFAOYSA-N 3-triethoxysilylpropane-1-thiol Chemical compound CCO[Si](OCC)(OCC)CCCS DCQBZYNUSLHVJC-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- SPNJNGBLQSTLMI-UHFFFAOYSA-N CC(C)=NN.NNC1=CC=NC=C1C(=O)ON1C(=O)CCC1=O Chemical compound CC(C)=NN.NNC1=CC=NC=C1C(=O)ON1C(=O)CCC1=O SPNJNGBLQSTLMI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000004214 Fast Green FCF Substances 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229910000708 MFe2O4 Inorganic materials 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229910001308 Zinc ferrite Inorganic materials 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- LDGFBSJHGXDMJE-UHFFFAOYSA-N [diacetyloxy(hexadecyl)silyl] acetate Chemical compound CCCCCCCCCCCCCCCC[Si](OC(C)=O)(OC(C)=O)OC(C)=O LDGFBSJHGXDMJE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000012741 allura red AC Nutrition 0.000 description 1
- 239000004191 allura red AC Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 238000001636 atomic emission spectroscopy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940090961 chromium dioxide Drugs 0.000 description 1
- IAQWMWUKBQPOIY-UHFFFAOYSA-N chromium(4+);oxygen(2-) Chemical compound [O-2].[O-2].[Cr+4] IAQWMWUKBQPOIY-UHFFFAOYSA-N 0.000 description 1
- AYTAKQFHWFYBMA-UHFFFAOYSA-N chromium(IV) oxide Inorganic materials O=[Cr]=O AYTAKQFHWFYBMA-UHFFFAOYSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001941 electron spectroscopy Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 230000005308 ferrimagnetism Effects 0.000 description 1
- 230000005307 ferromagnetism Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- RSKGMYDENCAJEN-UHFFFAOYSA-N hexadecyl(trimethoxy)silane Chemical compound CCCCCCCCCCCCCCCC[Si](OC)(OC)OC RSKGMYDENCAJEN-UHFFFAOYSA-N 0.000 description 1
- MCTWTUQSOKLGFJ-UHFFFAOYSA-N hexadecyl-dimethoxy-methylsilane Chemical compound CCCCCCCCCCCCCCCC[Si](C)(OC)OC MCTWTUQSOKLGFJ-UHFFFAOYSA-N 0.000 description 1
- 238000000920 holographic laser trapping Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 229960003988 indigo carmine Drugs 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000012432 intermediate storage Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000000651 laser trapping Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- SLYCYWCVSGPDFR-UHFFFAOYSA-N octadecyltrimethoxysilane Chemical compound CCCCCCCCCCCCCCCCCC[Si](OC)(OC)OC SLYCYWCVSGPDFR-UHFFFAOYSA-N 0.000 description 1
- MSRJTTSHWYDFIU-UHFFFAOYSA-N octyltriethoxysilane Chemical compound CCCCCCCC[Si](OCC)(OCC)OCC MSRJTTSHWYDFIU-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000009394 selective breeding Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 231100000527 sperm abnormality Toxicity 0.000 description 1
- 231100000521 sperm damage Toxicity 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910000314 transition metal oxide Inorganic materials 0.000 description 1
- PYJJCSYBSYXGQQ-UHFFFAOYSA-N trichloro(octadecyl)silane Chemical compound CCCCCCCCCCCCCCCCCC[Si](Cl)(Cl)Cl PYJJCSYBSYXGQQ-UHFFFAOYSA-N 0.000 description 1
- OYGYKEULCAINCL-UHFFFAOYSA-N triethoxy(hexadecyl)silane Chemical compound CCCCCCCCCCCCCCCC[Si](OCC)(OCC)OCC OYGYKEULCAINCL-UHFFFAOYSA-N 0.000 description 1
- FZMJEGJVKFTGMU-UHFFFAOYSA-N triethoxy(octadecyl)silane Chemical compound CCCCCCCCCCCCCCCCCC[Si](OCC)(OCC)OCC FZMJEGJVKFTGMU-UHFFFAOYSA-N 0.000 description 1
- AXNJHBYHBDPTQF-UHFFFAOYSA-N trimethoxy(tetradecyl)silane Chemical compound CCCCCCCCCCCCCC[Si](OC)(OC)OC AXNJHBYHBDPTQF-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- WGEATSXPYVGFCC-UHFFFAOYSA-N zinc ferrite Chemical compound O=[Zn].O=[Fe]O[Fe]=O WGEATSXPYVGFCC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/34—Purifying; Cleaning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/405—Concentrating samples by adsorption or absorption
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Electro-optical investigation, e.g. flow cytometers
- G01N15/1456—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Electro-optical investigation, e.g. flow cytometers without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G01N15/149—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0098—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation
Definitions
- the present invention relates to compositions comprising magnetic particles, the methods of using these compositions in processing animal sperm, the resulting sperm and embryo products, and the methods of use of these compositions to increase the efficiency, efficacy and/or speed of cell processing and artificial insemination techniques.
- Assisted reproductive technology includes such techniques as in vitro fertilization (IVF), artificial insemination (AI), intracytoplasmic sperm injection (ICSI) (other techniques using enucleated cells) and multiple ovulation and embryo transfer (MOET) (as well as other embryo transfer techniques) and is used across the animal kingdom.
- IVF in vitro fertilization
- AI artificial insemination
- ICSI intracytoplasmic sperm injection
- MOET multiple ovulation and embryo transfer
- ART methods are generally expensive, time consuming and marginally successful given the inherent fragility of gametes when outside of their natural environments.
- the use of ART within the animal breeding industry in a commercially feasible manner is additionally challenging due to the limited availability of genetically desirable gametes (sperm or oocytes).
- One way to lower the cost of ART and to improve its commercial feasibility is to increase the efficiency of the involved processes by improving the viability and overall quality of gametes used in ART.
- sex sorting An example of processing gametes prior to their use in ART is the sorting of sperm based on sex (known as “gender enrichment” or “sex sorting"), which is a now commonly used procedure to minimize wasted births of the wrong sex for selective breeding in the livestock industry. In some species, however, it is still cost prohibitive and can represent a financial risk to those with smaller breeding herds.
- Sex sorting includes processes that physically separate X and Y bearing sperm from each other into separate subpopulations, as well as processes in which sperm bearing the undesired sex chromosome in a sperm sample are selectively killed, compromised, disabled, rendered immotile, or otherwise rendered infertile by, for example, laser ablation/photo damage techniques to render a gender enriched population of sperm.
- sex sorting involves many harsh steps including but not limited to: the initial collection and handling of sperm ejaculate, which naturally starts to deteriorate rapidly upon collection; the staining of sperm, which involves binding of an excitable dye to the DNA or a harmful membrane selection procedure; the physical sorting of the sperm using high energy fluorescence that physically energizes the dye that is bound to the DNA, forced orientation through a narrow orifice, and application of an electrical charge to the cell; the physical collection of the cells into a receiving container, which often shocks the fragile cell upon contact; the osmotic stresses associated with dilution of the sperm droplet in collection media; and the storage of the sorted sperm usually by freezing, which is well known to raise havoc with the cell's membrane systems.
- Each step places the processed sperm under abnormal stress that diminishes the overall motility, viability and/or fertility of the sperm.
- the result can lead to less efficient samples for use in ART, such as IVF and AI, and other types of subsequent or further processing.
- Even non-sorted processed sperm exhibits significant losses in fertility, viability and motility when being collected, handled and transported without freezing, and noticeably experiences significant stress when mixed with cryoprotectant and frozen and thawed.
- Many in the field have tried to improve methods for the use on unsorted, conventional semen to minimize loss in the handling processes associated with in vitro handling, preservation and use of semen samples.
- sperm lose their potential to fertilize when exposed to: elevated temperatures, abnormal buffers, stains, altered pH systems, physical pressurized orientation as when forced through a nozzle or when oscillated to form drops in a flow cytometer, radiation used to illuminate the DNA binding dye, physical stressors associated with separation and collection techniques, cryoprotectants, freezing, thawing and micromanipulation by the handler.
- a broad object of the present invention is to provide improvements in the motility, viability, fertility and overall integrity of processed sperm, particularly sperm that undergo analysis and/or sex sorting.
- one aspect of the present invention broadly encompasses compositions comprising magnetic particles and the use of such compositions in the cell sorting process.
- Other aspects of the invention encompass methods of using sperm processed with magnetic particles in various ART procedures, including but not limited to, IVF, AI, ICSI and MOET.
- the invention comprises a composition for magnetic cellular manipulation comprising a plurality of particles.
- Each particle in the plurality of particles may include a magnetic substrate.
- the magnetic substrate may be characterized by a magnetic susceptibility greater than zero.
- Such particles are generally referred to hereinafter as particles or magnetic particles.
- Each particle in the plurality of particles may also include a chargeable silicon-containing compound.
- the chargeable silicon-containing compound may coat at least a portion of the magnetic substrate.
- a method for magnetic cellular manipulation may include contacting a composition with a biological sample to form a mixture.
- the composition may include a plurality of particles.
- Each particle in the plurality of particles may include a magnetic substrate.
- the magnetic substrate may be characterized by a magnetic susceptibility greater than zero.
- Each particle in the plurality of particles may include a chargeable silicon-containing compound.
- the chargeable silicon-containing compound may coat at least a portion of the magnetic substrate.
- the biological sample may include cells, such as sperm and/or cellular structures.
- the method may also include applying a magnetic field to the mixture to manipulate the composition.
- a kit for magnetic cellular manipulation may include instructions.
- the instructions may include contacting a composition with a biological sample to form a mixture.
- the instructions may also include applying a magnetic field to the mixture to manipulate the composition.
- the kit may also include the composition.
- the composition may include a plurality of particles. Each particle in the plurality of particles may include a magnetic substrate.
- the magnetic substrate may be characterized by a magnetic susceptibility greater than zero.
- Each particle in the plurality of particles may include a chargeable silicon-containing compound.
- the chargeable silicon-containing compound may coat at least a portion of the magnetic substrate.
- compositions comprising magnetic particles comprise sperm at a concentration of 500 x 10 6 cells/ml or less; 400 x 10 6 cells/ml or less; 300 x 10 6 cells/ml or less; 200 x 10 6 cells/ml or less; 180 x 10 6 cells/ml or less; 160 x 10 6 cells/ml or less; 120 x 10 6 cells/ml or less; 100 x 10 6 cells/ml or less; or 50 x 10 6 cells/ml or less.
- compositions comprising magnetic particles comprise 0.01-3 mg of magnetic particles per 100 million sperm; 0.1-2 mg of magnetic particles per 100 million sperm; 0.1-2 mg of magnetic particles per 100 million sperm; 0.2-1.8 mg of magnetic particles per 100 million sperm; 0.5-1.6 mg of magnetic particles per 100 million sperm; 0.7-1.5 mg of magnetic particles per 100 million sperm; 1.0-1.4 mg of magnetic particles per 100 million sperm; 1.1-1.3 mg of magnetic particles per 100 million sperm; or 1.125 mg of magnetic particles per 100 million sperm.
- the magnetic particles have a size distributions from about 300nm to about 800nm; about 50nm to about 400nm; about lnm to about ⁇ ; from about lOnm to about 900nm; from about lOnm to about 700nm; from about lOnm to about 500nm; from about lOnm to about 400nm; from about lOnm to about 300nm; from about lOnm to about 250nm; from about lOnm to about 200nm; from about lOnm to about 190nm; from about lOnm to about 180nm; from about lOnm to about 150nm; from about 20nm to about 700nm; from about 20nm to about 500nm; from about 20nm to about 400nm; from about 20nm to about 300nm; from about 20nm to about 250m; from about 20nm to about 200nm; from about 20nm to about 190nm; from about 20nm to about 180nm; from about l
- sex sorting of sperm may be accomplished using any process or device known in the art for cell analysis, sorting and/or population enrichment including but not limited to use of a flow cytometer or use of a micro fluidic chip.
- sex sorting in addition to encompassing techniques for physically separating, or isolating, X and Y bearing sperm from each other as with droplet sorting and fluid switching sorting, also encompasses techniques for gender enrichment in which sperm bearing the undesired sex chromosome are killed, immobilized, or otherwise rendered infertile, such as by use of laser ablation/photo damage techniques.
- compositions comprising magnetic particles may comprise one or more buffers, including but not limited to carbonates, phosphates, citrates, acetates, lactates, and combinations thereof, or a solution containing a salt, a carbohydrate, or a combination thereof can be employed in some of the embodiments of the invention, such as, but not limited to, Tris, TES, HEPES, TALP, TCA, PBS, citrate, milk and derivatives thereof, as discussed in detail in U.S. Patent 7,208,265 the contents of which is hereby incorporated by reference in its entirety.
- buffers including but not limited to carbonates, phosphates, citrates, acetates, lactates, and combinations thereof
- a solution containing a salt, a carbohydrate, or a combination thereof can be employed in some of the embodiments of the invention, such as, but not limited to, Tris, TES, HEPES, TALP, TCA, PBS, citrate, milk and derivatives thereof, as discussed in detail
- compositions comprising magnetic particles may comprise one or more chelators, including but not limited to, deferoxamine, deferasirox, penicillamine, alpha lipoic acid, DMPS, DMSA, dimercaprol and aminopolycarboxylic acids (complexones), including but not limited to Fura-2, IDA, NT A, EDTA, DTPA, EGTA, BAPTA, NOT A, DOTA and nicotianamine, and derivatives thereof.
- chelators including but not limited to, deferoxamine, deferasirox, penicillamine, alpha lipoic acid, DMPS, DMSA, dimercaprol and aminopolycarboxylic acids (complexones), including but not limited to Fura-2, IDA, NT A, EDTA, DTPA, EGTA, BAPTA, NOT A, DOTA and nicotianamine, and derivatives thereof.
- compositions comprising magnetic particles may comprise low sugar media.
- sugar refers to mono- or di- saccharides that are generally metabolized by mammalian sperm, e.g., glucose and fructose.
- saccharides that are generally metabolized by mammalian sperm, e.g., glucose and fructose.
- saccharides that are generally metabolized by mammalian sperm, e.g., glucose and fructose.
- saccharides e.g., glucose and fructose.
- low sugar media comprises less than about 50mM, 45mM, 40mM, 35mM, 30mM, 25mM, 20mM, 19mM, 18mM, 17mM, 16.5mM, 16mM, 15.5mM, 15mM, 14.5mM, 14mM, 13.5mM, 13mM, 12.5mM, 12mM, 11.5mM, l lmM,
- low sugar media comprises about l-5mM, 5-10mM, 10-15mM, 15-20mM, 20-25mM, 25-30mM, 35-40mM, or 45-50mM of sugar additive.
- low sugar media comprises about l-5mM, 1-lOmM, l-15mM, 1- 20mM, l-25mM, l-30mM, l-35mM, l-40mM, l-45mM, or l-50mM of sugar additive.
- low sugar media comprises about O. lppm to about 5mM, about O. lppm to about lOmM, about O. lppm to about 15mM, about O.
- low sugar media comprises about ImM, 2mM, 3mM, 4mM, 4. ImM, 4.2mM, 4.3mM, 4.4mM, 4.5mM, 4.6mM, 4.7mM, 4.8mM, 4.9mM, 5mM, 5.0mM, 5.
- low sugar media comprises about 1-lOmM, 2-9mM, 3-6mM, 4- 6mM, or 4-5mM of sugar additive. In yet another embodiment of the invention, low sugar media comprises about 5-15mM, 6-14mM, 7-13mM, 8-12mM, 9-1 ImM or 9-10mM of sugar additive. In yet another embodiment of the invention, low sugar media comprises no sugar additive or at most, trace amounts of sugar additive (i.e., no more than 0.1-20ppm of sugar additive).
- low sugar media comprises less than about 50mM, 45mM, 40mM, 35mM, 30mM, 25mM, 20mM, 19mM, 18mM, 17mM, 16.5mM, 16mM, 15.5mM, 15mM, 14.5mM, 14mM, 13.5mM, 13mM, 12.5mM, 12mM, 11.5mM, l lmM,
- low sugar media comprises about l-5mM, 5-10mM, 10-15mM, 15-20mM, 20-25mM, 25-30mM, 35-40mM, or 45-50mM of sugar.
- low sugar media comprises about l-5mM, 1-lOmM, l-15mM, l-20mM, l-25mM, l-30mM, l-35mM, 1- 40mM, l-45mM, or l-50mM of sugar.
- low sugar media comprises about O. lppm to about 5mM, about O. lppm to about lOmM, about O.lppm to about 15mM, about O. lppm to about 20mM, about O. lppm to about 25mM, about O.lppm to about 30mM, about O. lppm to about 35mM, about O.
- low sugar media comprises about ImM, 2mM, 3mM, 4mM, 4. ImM, 4.2mM, 4.3mM, 4.4mM, 4.5mM, 4.6mM, 4.7mM, 4.8mM, 4.9mM, 5mM, 5.0mM, 5.
- low sugar media comprises about 1-lOmM, 2-9mM, 3-6mM, 4-6mM, or 4-5mM of sugar. In yet another embodiment of the invention, low sugar media comprises about 5-15mM, 6-14mM, 7-13mM, 8-12mM, 9-1 ImM or 9-10mM of sugar. In another embodiment of the invention, low sugar media comprises no sugar or at most, trace amounts of sugar (i.e., no more than 0.1-20ppm of sugar).
- compositions comprising magnetic particles may comprise one or more "organic stress reducing” agents (OSRs), which may comprise an antioxidant, a vitamin or other organic molecule involved directly or indirectly in modulating physiological stresses in the cell.
- OSRs organic stress reducing agents
- compositions comprising magnetic particles may comprise one or more OSRs, each in the concentration range of 0.01 mg/ml to 5 mg/ml.
- OSRs can be used in the context of the current invention, including but not limited to: catalase, superoxide dismutase (SOD), SOD mimics, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, butylated hydroxytoluene (BHT), lipoic acid, flavins, quinones, vitamin K (and related vitamers), vitamin B12 (and related vitamers), with 'vitamers' defined as compounds having the same vitamin activity (such as cobalamin, cyanocobalamin,
- alpha-ketoglutarate also known as a-KG, AKG or oxo-glutarate
- various biological forms of AKG such as arginine, aspartate, lysine, and similar derivatives
- MDA malondialdehyde
- ADM A asymmetric dimethylarginine
- Certain embodiments of the invention utilize concentrations of OSRs selected from the following ranges: 0.01 to 5.0 mg/ml; 0.01 to 0.25 mg/ml; 0.01 to 0.5 mg/ml; 0.01 to 1 mg/ml; 0.01 to 2.5 mg/ml; 0.01 to 5 mg/ml; 0.05 to 0.1 mg/ml; 0.05 to 1.0 mg/ml; 0.05 to 2.5 mg/ml; 0.1 to 0.25 mg/ml ; 0.1 to 0.5 mg/ml; 0.1 to 1 mg/ml; 0.1 to 2.5 mg/ml; 0.1 to 5 mg/ml; 0.15 to 0.45 mg/ml; 0.15 to 0.5 mg/ml; 0.25 to 0.35 mg/ml;0.25 to 0.5 mg/ml; 0.25 to 1 mg/ml; 0.25 to 2.5 mg/ml; 0.25 to 5 mg/ml; 0.35 to 0.5 mg/ml; 0.35 to 1 mg/ml; 0.35 to 2.5 mg/ml; 0.35 to 5 mg
- compositions comprising magnetic particles may comprise one or more tricarboxylic acid cycle intermediates, including but not limited to, pyruvate, acetyl-CoA, citrate, isocitrate, a-ketoglutarate, succinyl-CoA, succinate, fumarate, malate, oxaloacetate, and derivatives thereof, including but not limited to isomers and acids.
- tricarboxylic acid cycle intermediates including but not limited to, pyruvate, acetyl-CoA, citrate, isocitrate, a-ketoglutarate, succinyl-CoA, succinate, fumarate, malate, oxaloacetate, and derivatives thereof, including but not limited to isomers and acids.
- compositions comprising magnetic particles comprises two or more tricarboxylic acid cycle intermediates, including but not limited to, pyruvate, acetyl-CoA, citrate, isocitrate, a- ketoglutarate, succinyl-CoA, succinate, fumarate, malate, oxaloacetate, and derivatives thereof, including but not limited to isomers and acids.
- tricarboxylic acid cycle intermediates including but not limited to, pyruvate, acetyl-CoA, citrate, isocitrate, a- ketoglutarate, succinyl-CoA, succinate, fumarate, malate, oxaloacetate, and derivatives thereof, including but not limited to isomers and acids.
- Certain embodiments of the invention utilize concentrations of a tricarboxylic acid cycle intermediate selected from the following ranges: 0.01 to 5.0 mg/ml; 0.01 to 0.25 mg/ml; 0.01 to 0.5 mg/ml; 0.01 to 1 mg/ml; 0.01 to 2.5 mg/ml; 0.01 to 5 mg/ml; 0.05 to 0.1 mg/ml; 0.05 to 1.0 mg/ml; 0.05 to 2.5 mg/ml; 0.1 to 0.25 mg/ml; 0.1 to 0.5 mg/ml; 0.1 to 1 mg/ml; 0.1 to 2.5 mg/ml; 0.1 to 5 mg/ml; 0.15 to 0.45 mg/ml; 0.15 to 0.5 mg/ml; 0.25 to 0.35 mg/ml;0.25 to 0.5 mg/ml; 0.25 to 1 mg/ml; 0.25 to 2.5 mg/ml; 0.25 to 5 mg/ml; 0.35 to 0.5 mg/ml; 0.35 to 1 mg/ml; 0.35 to 2.5 mg/m
- compositions comprising magnetic particles may comprise one or more cryoprotectants, including but not limited to, propylene glycol, dimethyl sulfoxide, ethylene glycol and glycerol, or a combination thereof.
- compositions comprising magnetic particles may comprise a concentration of cryoprotectant by percent volume selected from the following: less than 1%; 1-5%; 5%; 5 to 10%; 10%; 10 to 20%; 16.7%; 20%; 20 to 30%; or 30 to 40%.
- compositions comprising magnetic particles may comprise one or more antioxidants, including but not limited to catalase, superoxide dismutase (SOD), SOD mimics, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, butylatedhydroxytoluene (BHT), lipoic acid, flavonoids, phenolic acids and their esters, quinines, vitamin A (and related vitamers), vitamin C (and related vitamers), vitamin K (and related vitamers), vitamin B12 (and related vitamers), with "vitamers” defined as compounds having the same vitamin activity (such as cobalamin, cyanocobalamin, methylcobalamin, adenosylcobalamin, hydroxocobalamin, and pseudo-B12), vitamin E (including its vitamers, tocopherols ( ⁇ , ⁇ , ⁇ ), tocotrienols, and a-tocopheryl), a-
- antioxidants including
- Certain embodiments of the invention utilize concentrations of an antioxidant selected from the following ranges: 0.01 to 5.0 mg/ml; 0.01 to 0.25 mg/ml; 0.01 to 0.5 mg/ml; 0.01 to 1 mg/ml; 0.01 to 2.5 mg/ml; 0.01 to 5 mg/ml; 0.05 to 0.1 mg/ml; 0.05 to 1.0 mg/ml; 0.05 to 2.5 mg/ml; 0.1 to 0.25 mg/ml ; 0.1 to 0.5 mg/ml; 0.1 to 1 mg/ml; 0.1 to 2.5 mg/ml; 0.1 to 5 mg/ml; 0.15 to 0.45 mg/ml; 0.15 to 0.5 mg/ml; 0.25 to 0.35 mg/ml;0.25 to 0.5 mg/ml; 0.25 to 1 mg/ml; 0.25 to 2.5 mg/ml; 0.25 to 5 mg/ml; 0.35 to 0.5 mg/ml; 0.35 to 1 mg/ml; 0.35 to 2.5 mg/ml; 0.35 to 5 mg/
- compositions comprising magnetic particles may comprise one or more protein sources, including but not limited to, egg yolk, egg yolk extract, milk (including heat homogenized and skim), milk extract, soy protein, soy protein extract, serum albumin, bovine serum albumin, human serum substitute supplement, seminal proteins, such as, for example, whole seminal plasma or seminal plasma extracts, and derivatives thereof.
- compositions comprising magnetic particles may comprise a concentration of protein source by percent volume selected from the following: 1-5%; 5%; 5 to 10%>; 10%>; 10 to 20%; 16.7%; 20%; 20 to 30%; or 30 to 40%.
- compositions comprising magnetic particles may comprise one or more antimicrobial or antibiotic agents, including but not limited to, tylosin, gentamicin, lincomycin, spectinomycin, Linco-Spectin® (lincomycin hydrochloride- spectinomycin), penicillin, streptomycin, ticarcillin, polymyxin B, and their derivatives. If included, the antibiotics may be present in a concentration of about 50 ⁇ g to about 800 ⁇ g per ml of semen.
- compositions comprising magnetic particles may comprise a detergent, including but not limited to, an alkyl ionic detergent such as sodiumdodecyl sulfate (SDS).
- SDS sodiumdodecyl sulfate
- compositions comprising magnetic particles may comprise one or more salts, including but not limited to, NaCl, KC1, MgCl 2 , CaCl 2 and any combination of a salt-forming anion, including but not limited to acetate (CH3COO ), carbonate (CO3 2 ), chloride (CI " ), citrate (HOC(COO )(CH2COO ) 2 ), fluoride (F ), nitrate (NO3 ), nitrite ( O2 " ), phosphate (P0 4 3 ) and sulfate (S0 4 2 ) and a salt-forming cation, including but not limited to, ammonium (NH 4 + ), calcium (Ca 2+ ), iron (Fe 2+ and Fe 3+ ), magnesium (Mg 2+ ), potassium (K + ), pyridinium (C5H5NF , quaternary ammonium NR 4 + and sodium (Na + ).
- a salt-forming anion including but not limited to
- compositions comprising magnetic particles may comprise one or more growth factors including but not limited to transforming growth factors (“TGF”), such as, for example, TGFP-l and TGFP-2, and insulin-like growth factors (“IGF”), such as for example, IGF-1.
- TGF transforming growth factors
- IGF insulin-like growth factors
- DNA selective dyes for use with the invention include but are not limited to UV light excitable, selective dyes, such as Hoechst 33342 and Hoechst 33258 and visible light excitable dyes, such as SYBR-14 and bisbenzimide-BODIPY® conjugate 6- ⁇ [3-((2Z)-2- ⁇ [l-(difluoroboryl)-3,5-dimethyl-lH-pyrrol-2yl] methylene ⁇ -2H- pyrrol-5-yl)propanoyl]amino ⁇ -N-[3- (methyl ⁇ 3- [( ⁇ 4- [6- (4-methylpiperazin-l-yl) -1H,3 'H- 2,5 'bibenzimidazol-2 ' - yljphenoxy ⁇ acetyl)amino]propyl ⁇ amino)propyl]hexanamide.
- UV light excitable, selective dyes such as Hoechst 33342 and Hoechst 33258 and visible
- the staining solution further comprises one or more dye quenchers, including but not limited to F&DC red food dye No. 40 and yellow food dye No. 4.
- the staining solution further comprises one or more OSRs.
- the concentration of dye in the staining solution is from about ⁇ . ⁇ to about 1.0M; from about ⁇ . ⁇ to about 1000 ⁇ ; from about ⁇ to about 500 ⁇ ; from about 200 ⁇ to about 500 ⁇ ; from about 300 ⁇ to about 450 ⁇ ; about 350 ⁇ ; about 400 ⁇ ; or about 450 ⁇ .
- compositions comprising magnetic particles of the invention may be maintained at any of a range of pHs suitable for the particular process and sperm type. In certain embodiments, this will be in the range of about 5.0 to about 9.0; in the range of 5.5 to about 7.8; from about 5.0 to about 7.0; from about 6.0 to about 7.0; from about 6.0 to about 6.5; from about 6.0 to about 8.0; from about 6.5 to about 7.5; from about 6.8 to about 7.4; from about 7.0 to about 9.0; from about 7.0 to about 8.0; from about 7.0 to about 7.5; about 6.2, about 6.5; about 6.6; about 6.7; about 6.8; about 6.9; about 7.0; about 7.1; about 7.2; about 7.3; about 7.35; about 7.4; or about 7.5; about 7.6, about 7.7, about 7.8, about 7.9; or about 8.0.
- magnetic particles may be combined with a sperm sample to form a sperm composition.
- sperm sample may comprise a processed semen sample or an unsorted, conventional semen sample.
- the sperm composition comprising magnetic particles is used to process sperm for use in ART.
- Such ART techniques involve different levels of gamete cell processing which in the case of sperm can entail, by example only and is not limited to one or more of the following: artificially collecting a semen sample from the male animal that may involve natural, electronic or other types of sexual stimulation; holding; transporting; buffering with different pHs; chilling; warming; staining; diluting; concentrating; energetically exciting as with a laser; electronic charging; deflecting; ablating to kill unwanted cells usually with targeted lasers; sorting; collecting; shaking;
- microinjecting micro fluidic processing; microchip processing; jet and air processing; flow cytometry processing; and similar handling techniques.
- a single processing step may exert only minimal stress on a sperm, others or a combination may add significant stress, often killing the cell.
- An example is the sex sorting process used to separate X- from Y-chromosome bearing cells; the sorting process combines a large number of independent stressful steps that may compromise the overall integrity of the sorted sperm population.
- a sperm composition comprising a sperm sample and magnetic particles can be used immediately or processed within the first few minutes after the magnetic particles are added to the sperm sample for whatever processing step is needed, whereby the holding period would be in the range of 1 to 2 seconds; 1 to 10 seconds; 1 to 20 seconds; 20 to 30 seconds; 30 seconds to 1 minute; 1 to 2 minutes; 1 second to 3 minutes; 1 minute to 5 minutes; or 1 minute to 10 minutes.
- holding periods can be longer, as in the range of a 1 minute to 15 minutes, the range of 15 minutes to 1 hour or up to about 8 hours or overnight for extensive processing such as with sex sorting techniques.
- magnetic particles are used several times during a complex processing procedure. In other embodiments, magnetic particles are used only at one or more particular steps.
- magnetic particles can be used during the staining process during sex sorting, which is often performed at non-physiological pH and at elevated temperatures.
- magnetic beads can be used just prior to cryopreservation of sperm or after thawing of cryopreserved sperm.
- a further embodiment of the present invention provides a method of improving the motility, viability and/or fertility of a sperm sample that has already undergone a sorting process, including but not limited to sex sorting, comprising the step of contacting or adding a sorted sperm sample to magnetic particles and then subsequently removing the magnetic particles.
- Another broad object of the present invention is to improve the motility, viability (including longevity and ability to survive environmental stress) and fertility of processed and/or sorted sperm for use in ART such as IVF, AI, ICSI (as well as other techniques using enucleated cells), and MOET (as well as other embryo transfer techniques).
- Some embodiments of the invention encompass compositions comprising magnetic particles comprising a sorted or processed sperm sample, and optionally at least one OSR in the range of 0.01 mg/ml to 5 mg/ml, for use in ART.
- a further embodiment of the invention resides in a method of making an embryo comprising mixing at least one egg with one or more sperm from a sperm sample that has been contacted with magnetic particles.
- the embryos produced by this method constitute a further embodiment of the invention.
- Another embodiment of the invention includes a method for inseminating an organism through an AI technique using a processed or sorted sperm sample contacted with magnetic particles.
- the progeny of the organism that results from the aforementioned AI method also constitutes an embodiment of the invention.
- a further embodiment of the invention includes a method for inseminating an organism through an AI technique using a processed or sorted sperm sample contacted with magnetic particles.
- Embodiments of the invention can include sperm, or spermatozoa, collected from numerous species of male animals, and the invention should be understood not to be limited to the species of male animals described by the specific examples within this application. Rather the specific examples within this application are intended to be illustrative of the varied and numerous species of male animals from which semen can be collected and utilized in certain embodiments of the invention.
- Embodiments of the invention may include the sperm of humans as well as animals having commercial value for meat or dairy production such as swine, ovine, bovine, equine, deer, elk, buffalo, or the like (naturally the mammals used for meat or dairy production may vary from culture to culture).
- It may also include the sperm of various domesticated mammalian species encompassed by canines and felines, as well as sperm of primates, including but not limited to chimpanzees, gorillas, or humans and the spermatozoa from whales, dolphins and other marine mammals. It may also include frozen-thawed sperm from all the various mammals above-described and further, including but not limited to, the sperm of deceased donors, from rare or exotic mammals, zoological specimens, or endangered species.
- a particular embodiment of the invention comprises a method of sorting a sperm sample to form one or more subpopulations comprising the steps of providing a sperm sample, sorting the sperm sample to form one or more subpopulations and using magnetic particles during one or more of the aforementioned sorting steps.
- magnetic particles may be used in a diluent for diluting sperm, a staining solution for staining the sperm with, for example, a DNA selective dye, a sheath fluid for encapsulating the core stream containing the sperm as it passes through the flow cytometer, a catch media for receiving one or more of the sorted sperm subpopulations, or a resuspension media for resuspending processed sperm.
- compositions comprising a gender enriched sperm population, created for example by way of separation or photo/laser abalation, and magnetic particles.
- Another embodiment of the invention encompasses a method of processing sperm comprising the steps of forming a composition comprising said sperm and magnetic particles; removing said magnetic particles from said composition; forming a stream comprising said sperm; determining a property of said sperm in said stream; and selecting sperm having a property of interest from said sperm in said stream.
- the steps of forming a composition comprising said sperm and magnetic particles and removing said magnetic particles from said composition are performed after the step of selecting sperm having a property of interest from said sperm in said stream.
- the steps of forming a composition comprising said sperm and magnetic particles and removing said magnetic particles from said composition are performed before the step of forming a stream comprising said sperm.
- magnetic particles that have been removed from a composition comprising sperm are washed one or more times in a suitable media in order to extract any viable and/or uncompromised sperm that may have adhered to the particles.
- Figure 1 is a schematic representation of part of a flow cytometer illustrating a method of sorting a sperm sample into one or more subpopulations according to some embodiments of the present invention.
- Figure 2 shows the results of ICP and Zeta analysis of multiple lots of magnetic particles.
- Figures 3 and 4 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 2.
- Figure 5 shows post-thaw motility and viability of sperm treated with magnetic particles in Example 2.
- Figures 6 and 7 show various sort parameters and percentage of dead sperm removed by sonicated and non- sonicated magnetic particles in Example 2.
- Figure 8 shows post-thaw motility and viability of sperm treated with sonicated and non- sonicated magnetic particles in Example 2.
- Figure 9 is a flow cytometer image indicating the percentage of dead sperm removed by magnetic particles.
- Figures 10 and 11 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 5.
- Figures 12-14 show post-thaw motility and viability of sperm treated with magnetic particles in Example 5.
- Figures 15 and 16 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 6.
- Figures 17 and 18 show post-thaw motility of sperm treated with magnetic particles in Example 6.
- Figure 19 shows quality control analysis results for 8 bulls used in Example 7.
- Figures 20-22 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 7.
- Figure 23 shows post-thaw motility and viability of sperm treated with magnetic particles in Example 7.
- Figure 24 shows IVF trial results using sperm treated with magnetic particles in Example 7.
- Figure 25 shows Zeta potential distribution form magnetic particles produced according to Example 9.
- Figures 26 and 27 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 10.
- Figure 28 shows various sort parameters and percentage of dead sperm removed by magnetic particles in Example 11.
- Figures 29 and 30 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 12.
- Figures 31 and 32 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 13.
- Figures 33 and 34 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 14.
- Figures 35, 36 and 38-40 show various sort parameters and percentage of dead sperm removed by magnetic particles in Example 15.
- Figures 37 and 41 show post-thaw motility and viability of sperm treated with magnetic particles in Example 15.
- Figure 42 shows IVF trial results using sperm treated with magnetic particles in Example 15.
- the invention broadly encompasses methods and compositions comprising magnetic particles for processing sperm. It has been discovered that the use of magnetic particles for processing sperm improves the relative number of viable and/or uncompromised sperm relative to dead and/or compromised sperm in a sample, as well as the overall quality of the processed sperm, including but not limited to increased motility, viability and fertility. Furthermore, by decreasing the number of dead and/or compromised sperm in a sample prior to sex sorting, the overall speed and efficiency of the sex sorting process can be increased. The net result is higher quality, lower cost gender enriched sperm that can be used in ART.
- embodiments of the described methods and processes include a method for removing or identifying cells or cellular structures having damaged membranes from those with intact membranes, thereby enriching sample, or cellular, viability and quality.
- the method may be applied to cells such as contained in freshly collected samples, after dilution, during and after cooling, or during and after other cell or system procedures that may be employed prior to, or after, cryopreservation, or to frozen/thawed cell samples.
- the method may also be used for samples that may be used immediately.
- the method may also be used for samples that may be held for a period of time or extended in buffers or other substances.
- the method may also be used for samples that may be held at 4° C to 40° C for at least about 12, 24, 30, 36, 48, 60, 72 hours or more.
- the method may also be used for samples that include but are not limited to samples that have an osmolality of 250-375 mOsm.
- the enriched cell populations may be used for routine procedures, prior to or after other processing techniques, prior to or after shipment of samples, and prior to or after long-term cryopreservation or other processes.
- Embodiments related to sperm may include a method for removing sperm having damaged membranes from those with intact membranes to enrich sperm viability of a sperm sample.
- the method may be applied to sperm contained in freshly collected neat ejaculates, after dilution, during and after cooling, or during and after other semen processing procedures that may be employed prior to, or after, cryopreservation, or to frozen/thawed sperm.
- the method may also be used for neat or extended sperm samples to be used immediately.
- the method may also be used for neat or extended sperm samples held up to 30 h at 4° C to 40° C, or extended in sperm rich buffers that have an osmolality of 250-375 mOsm.
- the enriched sperm populations may be used for routine artificial insemination, prior to or after sperm sexing techniques, prior to or after shipment of semen for routine or sperm sexing purposes or cryopreservation purposes, or for in vitro fertilization, for all mammalian sperm.
- damage to the membranes of intact cells may be reduced by removing known harmful effects caused by damaged cells.
- DNA fragmentation, oxidative damage caused by peroxidation, and the premature release of proteolytic and hydrolytic enzymes may be examples of effects attributable to membrane damage. Damage to cell sample integrity may reduce lifespan both in vitro and in vivo, may reduce desired cellular functional ability, and may cause poor resultant capabilities.
- damage to the membranes of intact sperm may be reduced by removing known harmful effects caused by damaged sperm.
- DNA fragmentation, oxidative damage caused by peroxidation, and the premature release of proteolytic and hydrolytic enzymes may be examples of sperm damage caused by membrane damaged sperm.
- Damage to spermatozoal integrity may reduce sperm lifespan both in vitro and in vivo, may reduce fertilization ability, and likely causes poor embryo quality, which may be a major source of infertility in mammals.
- Mammalian sperm with good fertility may exhibit a high frequency of morphologically- normal, viable sperm.
- Current procedures for semen processing for sex selection, cooling, or cryopreservation may have detrimental effects on the metabolism and motility of sperm, as well as on the status of sperm membrane domains. The net result of these effects may be reduced sperm functionality.
- Magnetic removal of damaged or compromised cells or cellular structures may reduce a detrimental effect on the quality of live and normal sperm that may be caused by dead and abnormal sperm.
- the carboxyl modified silane surface binds to the membrane of the dead and dying sperm through an electrical charge interaction known as zeta potential.
- Material may spontaneously acquire a positive or negative surface electrical charge when brought into contact with a polar medium (e.g., water).
- a polar medium e.g., water
- an interface in deionized water may be negatively charged.
- An ionization of surface groups to form a surface electrical charge may be observed with metal oxide surfaces (M-OH) as well as materials that may contain carboxyl and/or amino groups, such as proteins, ionic polymers, and polyelectrolytes. Ionization and/or dissociation, degree of charge development, net molecular charge, and sign, either positive or negative, may depend on the pH of the surrounding medium.
- the conjugation of carboxyl group functional magnetic particles may additionally be applied to, for example, fluorescent stains.
- SYBR-14 and bis-benzimide are example membrane permeable stains that may be used to distinguish cells from other background substances.
- fluorescent stains may distinguish sperm cells from diluent particles frequently found in extenders employed in non- frozen storage or cryopreservation of sperm.
- Other examples of fluorescent probes may include JC-1 and rhodamine 123, which may be used to assess the respiration rate of cell mitochondria; or fluorescently labeled agglutins from the pea (PSA) or peanut (PNA) that may be used to detect acrosome-reacted cells such as sperm.
- labels include but are not limited to acridine orange (e.g., to remove apoptotic cells); 7- aminoactinomycin D (7-AAD), which may be also a DNA intercalating agent in double stranded DNA with a high affinity for GC rich regions; food coloring such as Allura Red (FD&C Red #40), Sunset Yellow (FD&C Yellow #6), Indigo carmine (FD&C Blue #2), and Fast Green FCF (FD&C #3).
- acridine orange e.g., to remove apoptotic cells
- 7-AAD 7- aminoactinomycin D
- food coloring such as Allura Red (FD&C Red #40), Sunset Yellow (FD&C Yellow #6), Indigo carmine (FD&C Blue #2), and Fast Green FCF (FD&C #3).
- cells with varying degrees of membrane damage may be labeled with magnetic particles containing a charged surface. This may be in contrast to the use of annexin-V/microbead magnetic cell sorting procedures that fail to identify and/or remove pre-capacitated or acrosomal reacted sperm because the PS does not become externalized in these examples.
- annexin-V/microbead magnetic cell sorting procedures that fail to identify and/or remove pre-capacitated or acrosomal reacted sperm because the PS does not become externalized in these examples.
- the resultant harvested sub- population of viable cells may be further processed for cryopreservation, non-frozen transport and storage, functional utilization (such as sex selection for sperm), or used in related aspects, perhaps such as assisted reproductive technologies (ARTs) for sperm or the like.
- ARTs assisted reproductive technologies
- Embodiments of the described methods and processes may be used with any type of magnetically identifying separating apparatus, including but not limited to devices incorporating columns, such as magnetic-activated cell sorting (MACS) products, devices using simple magnetic fields applied to test tubes or containers, or high throughput magnetic devices.
- devices incorporating columns such as magnetic-activated cell sorting (MACS) products, devices using simple magnetic fields applied to test tubes or containers, or high throughput magnetic devices.
- MCS magnetic-activated cell sorting
- Magnetic cell separation may be utilized with no internal operating pressure, or if pressurized, a lower internal operating pressure; and the stream of fluid containing the cells may avoid being broken into cell damaging droplets as for flow cytometry.
- the sheath fluid for flow cytometry may be generally a salt- based, lipoprotein-deficient physiological medium. Magnetic cell separation may allow some cells, such as sperm, to be bathed in nutrient-rich buffers that may promote and prolong cell viability during the separation procedure.
- the described methods and processes may remove necrotic cells or cellular structures that have been traumatized during cell processing procedures such as cryopreservation, centrifugation, and staining. Necrotic damage may occur by different cellular processes than that caused in one example by sperm senescence, which may be a naturally occurring cause of cellular death.
- embodiments of the described methods and processes may be used to label cells uniquely, such as sperm, with one or more fluorochrome stains, targeting a specific cell or sperm attribute.
- the targeted cell or sperm cell may be selectively killed or rendered non- functional, with an energy source, including but not limited to an electrical charge or pulse of laser light.
- the described methods and processes may be used to magnetically label and ultimately remove the non- functional cell or sperm through magnetic cell separation procedures.
- the resultant desired sub-population of harvested cells may be selected for membrane intactness (viability) as well as for specific cellular attributes, including but not limited to, in the sperm example, chromosomal sex selection.
- a composition for magnetic cellular manipulation may include a plurality of particles.
- Each particle in the plurality of particles may include a magnetic substrate.
- the magnetic substrate may be characterized by a magnetic susceptibility greater than zero.
- Each particle in the plurality of particles may also include a chargeable silicon-containing compound.
- the chargeable silicon-containing compound may coat at least a portion of the magnetic substrate.
- Magnetic susceptibility means the response of a sample, such as the magnetic substrate, to an externally applied magnetic field.
- a magnetic susceptibility of less than or equal to zero may be associated with diamagnetism.
- a magnetic susceptibility of greater than zero may be associated with magnetic properties other than diamagnetism.
- the magnetic substrate may be characterized by one or more of
- the magnetic substrate may include a metal oxide, such as a transition metal oxide, for example, an iron oxide.
- the magnetic substrate may include Fe30 4 .
- a “chargeable silicon-containing compound” is any silicon containing molecule, polymer, or material that may be caused to acquire or hold a charge, e.g., via functionalization with charged or chargeable moieties.
- Chargeable/charged moieties may include, but are not limited to, species (and ions thereof) of: metals; oxides; carboxylates; amines; amides;
- the chargeable silicon-containing compound may include 2- (carbomethoxy)ethyltrimethoxysilane.
- the composition may include a zeta potential charge.
- the chargeable silicon-containing compound may include a negative zeta potential charge.
- the chargeable silicon-containing compound may include a positive zeta potential charge.
- at least a portion of the plurality of particles may include a first zeta potential charge.
- the portion of the plurality of particles may form a complex with one or more cells or cellular structures that include a second zeta potential charge.
- the second zeta charge may be opposite in sign compared to the first zeta charge.
- at least a portion of the plurality of particles may include a negative zeta potential charge.
- the portion of the plurality of particles may form a complex with one or more sperm cells or sperm cellular structures that include a positive zeta potential charge.
- a method for magnetic cellular manipulation may include contacting a composition with a biological sample to form a mixture.
- the composition may include a plurality of particles.
- Each particle in the plurality of particles may include a magnetic substrate.
- the magnetic substrate may be characterized by a magnetic susceptibility greater than zero.
- Each particle in the plurality of particles may include a chargeable silicon-containing compound.
- the chargeable silicon-containing compound may coat at least a portion of the magnetic substrate.
- the biological sample may include cells and/or cellular structures.
- the method may also include applying a magnetic field to the mixture to manipulate the composition.
- a "biological sample” may include any natural or prepared composition that includes the cells and/or cellular structures.
- Natural samples may include, for example, biological fluids containing cells or cellular structures, such as blood, lymphatic fluids, intestinal fluids, intercellular fluids, sweat, tears, urine, semen, mucosal secretions, synovial fluid, and the like. Natural samples may include fluids typically free of cells or cellular structures, but which may include cells or cellular structures as part of injury, illness, genetic defect, or other pathological conditions.
- Prepared samples may include any biopsy, tissue homogenate, or other prepared form of biological tissue.
- the biological sample will include at least one cell or cellular structure characterized by a zeta potential charge.
- the biological sample may include at least two or more cells or cellular structures characterized by zeta potential charges differing in sign or charge density.
- a biological sample may include a first cell characterized by a first zeta potential charge and a second cell characterized by a second zeta potential charge opposite in sign to the first zeta potential charge.
- the method may include causing the chargeable silicon-containing compound to acquire a first zeta potential charge.
- the first zeta potential charge may be opposite in sign compared to a second zeta potential charge comprised by the cells and/or cellular structures in the biological sample.
- Causing the chargeable silicon-containing compound to acquire the first zeta potential charge may include contacting the chargeable silicon-containing compound to a polar medium, as described herein.
- the method may include causing the composition and at least a portion of the cells and/or cellular structures in the biological sample to form a complex.
- Applying the magnetic field to the mixture to manipulate the composition may manipulate the complex.
- At least a portion of the plurality of particles further comprises at least one of a protein, an antibody, and a dye.
- the biological sample may include viable cells and damaged or compromised cells or cellular structures.
- the composition may selectively form a complex with one of the viable cells or the damaged or compromised cells or cellular structures, for example according to a first zeta potential charge on the composition and an opposite second zeta potential charge on one of the viable cells or the damaged or compromised cells or cellular structures.
- the method may further include separating the viable cells from the damaged or compromised cells or cellular structures by applying the magnetic field to the mixture. Because the composition may selectively form a complex with one of the viable cells or the damaged or compromised cells or cellular structures, the portion of the biological sample forming the complex with the composition may be magnetically manipulated and separated from portions of the biological sample not forming the complex with the composition.
- the method may therefore be a method for selectively and magnetically separating portions of the biological sample according to zeta potential charge.
- the biological sample may include viable sperm cells and damaged or compromised sperm cells or sperm cellular structures.
- the composition may form a complex with the damaged or compromised sperm cells or sperm cellular structures.
- the method may further include separating the viable sperm cells from the complex including the damaged or compromised sperm cells or sperm cellular structures by applying the magnetic field to the mixture. Because the composition may selectively form a complex with the damaged or compromised sperm cells or sperm cellular structures, the complex with the damaged or compromised sperm cells or sperm cellular structures may be magnetically manipulated and separated from the viable sperm cells.
- the method may therefore be a method for selectively and magnetically separating viable sperm cells from the damaged or compromised sperm cells or sperm cellular structures according to zeta potential charge.
- the method may include subjecting the sperm sample to detection, for example fluorescence detection as described herein.
- a kit for magnetic cellular manipulation may include instructions.
- the instructions may include contacting a composition with a biological sample to form a mixture.
- the instructions may also include applying a magnetic field to the mixture to manipulate the composition.
- the kit may also include the composition.
- the composition may include a plurality of particles. Each particle in the plurality of particles may include a magnetic substrate.
- the magnetic substrate may be characterized by a magnetic susceptibility greater than zero.
- Each particle in the plurality of particles may include a chargeable silicon-containing compound.
- the chargeable silicon-containing compound may coat at least a portion of the magnetic substrate.
- the biological sample may include viable cells and damaged or compromised cells or cellular structures.
- the composition may form a complex with one of the viable cells or the damaged or compromised cells or cellular structures.
- the instructions may further include separating the viable cells from the damaged or compromised cells or cellular structures by applying the magnetic field to the mixture.
- the composition may be configured for forming a complex with damaged or compromised sperm cells or sperm cellular structures.
- the instructions may further include selecting the biological sample comprising viable sperm cells and damaged or compromised sperm cells or sperm cellular structures.
- the instructions may also include separating the viable sperm cells from the complex including the damaged or compromised sperm cells or sperm cellular structures by applying the magnetic field to the mixture.
- Processing steps to which sperm are commonly subjected, and with which the invention may be used before, during or after, include, but are not limited to, collecting from a male animal, which may involve natural, electronic or other types of sexual stimulation; holding; transporting; buffering; chilling; warming; staining; diluting; concentrating; energetically exciting (as with a laser, for example); electronic charging; deflecting; ablating to kill unwanted cells usually with targeted lasers; sorting; collecting; shaking; oscillating; magnetically separating; oxygenating as associated with microchip sorting procedures; labeling; precipitating; centrifuging; resuspending; mixing; dialyzing; cryostabilizing; freezing; vitrifying;
- cryopreserving thawing; culturing; inseminating; microinjecting; microf uidic processing;
- microchip processing jet and air processing; flow cytometry processing; and similar handling techniques.
- the initial processing step is typically collection of a sperm sample from a male.
- the sperm sample is collected into an extender or diluent designed to sustain the cells until further processing or use.
- semen is collected and then subsequently diluted with an extender after collection.
- One embodiment of the invention encompasses processing collected semen with magnetic particles during or subsequent to collection.
- compositions comprising magnetic particles are used in the sorting process, including but not limited to the staining solution, sheath fluid and catch media, and prior to and after cryopreservation of such processed cells.
- bovine sperm sample typically containing about 0.5 to about 10 billion sperm per milliliter, may be collected directly from the source mammal, or from more than one source mammal of the same species, into a vessel containing magnetic particles to form a sperm composition.
- the sperm composition may optionally comprise one or more OSRs, which may be present as constituents of the composition comprising magnetic particles prior to contacting with the sperm, or which may be added to the sperm composition, each OSR in the concentration range of 0.01 mg/ml to 5 mg/ml.
- the magnetic particles may be subsequently removed from the sperm composition prior to any further processing steps.
- sperm compositions that pass these quality checks can then be prepared for further processing, such as sorting.
- the CASA motility variables measured can be a percentage of total motile sperm (motile), percentage of progressively motile sperm (progressive), VAO, VSL, curvilinear velocity (VCL, um/s), average lateral head displacement (ALK, um) and the number of times the sperm head crosses the mean path/s (BCF, Hz), straight-line sperm motility (STR, %), and linear sperm motility (LIN, %).
- OSRs can be used in the context of the current invention, including but not limited to catalase, superoxide dismutase (SOD), SOD mimics, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, butylated hydroxytoluene (BHT), lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12 (and related vitamers), with 'vitamers' defined as compounds having the same vitamin activity (such as cobalamin, cyanocobalamin, methylcobalamin, adenosylcobalamin, hydroxocobalamin, and pseudo-B12), vitamin E (including its vitamers, tocopherols ( ⁇ , ⁇ , ⁇ ), tocotrienols,
- the semen sample may be collected into an empty vessel and then subsequently contacted with magnetic particles within several minutes to hours after collection to form the sperm composition.
- the sperm composition may also contain a range of additives, including but not limited to the aforementioned OSRs, chelators, tricarboxylic acid cycle intermediates, cryoprotectants, sterols, lipids, fatty acids, protein sources, antibiotics, growth factors, caproic acid, catalase, Caprogen (caproic acid, catalase, and 5% egg yolk) detergents, including alkyl ionic detergents such as sodiumdodecyl sulfate (SDS).
- SDS sodiumdodecyl sulfate
- Exemplary buffers for use in the invention include, but are not limited to, carbonates, phosphates, citrates, acetates, lactates, and combinations thereof.
- Specific buffers that may be used include, but are not limited to, Tris, TES, Pipes, HEPES, TALP, TCA, PBS, citrate, milk and derivatives thereof, which are discussed in detail in U.S. Patent 7,208,265 the contents of which is hereby incorporated by reference in its entirety.
- Exemplary chelators for use in the invention include, but are not limited to, deferoxamine, deferasirox, penicillamine, alpha lipoic acid, DMPS, DMSA, dimercaprol and aminopolycarboxylic acids (complexones), including but not limited to Fura-2, IDA, NT A, EDTA, DTPA, EGTA, BAPTA, NOT A, DOTA and nicotianamine, and derivatives thereof.
- Exemplary tricarboxylic acid cycle intermediates for use in the invention include, but are not limited to, pyruvate, acetyl-CoA, citrate, isocitrate, a-ketoglutarate, succinyl-CoA, succinate, fumarate, malate, oxaloacetate, and derivatives thereof, including but not limited to isomers and acids.
- magnetic particles comprises two or more tricarboxylic acid cycle intermediates, including but not limited to, pyruvate, acetyl-CoA, citrate, isocitrate, a- ketoglutarate, succinyl-CoA, succinate, fumarate, malate, oxaloacetate, and derivatives thereof, including but not limited to isomers and acids.
- tricarboxylic acid cycle intermediates including but not limited to, pyruvate, acetyl-CoA, citrate, isocitrate, a- ketoglutarate, succinyl-CoA, succinate, fumarate, malate, oxaloacetate, and derivatives thereof, including but not limited to isomers and acids.
- cryoprotectants for use in the invention include but are not limited to propylene glycol, dimethyl sulfoxide, ethylene glycol and glycerol, or a combination thereof.
- magnetic particles may comprise a concentration of cryoprotectant by percent volume (w/v) selected from the following: 1-5%; 5%; 5 to 10%; 10%; 10 to 20%; 16.7%; 20%; 20 to 30%; or 30 to 40%.
- Exemplary protein sources for use in the invention include egg yolk, egg yolk extract, milk (including heat homogenized and skim), milk extract, soy protein, soy protein extract, serum albumin, bovine serum albumin, human serum substitute supplement, seminal proteins, such as, for example, whole seminal plasma or seminal plasma extracts (see, for example, Parks et al., Sperm Membrane Phospholipid Peroxidation and Fragmentation: Effects on Sperm
- compositions comprising magnetic particles may comprise a concentration of protein source by percent volume selected from the following: 1-5%; 5%; 5 to 10%; 10%; 10 to 20%; 16.7%; 20%; 20 to 30%; or 30 to 40%.
- Albumin and more particularly bovine serum albumin (BSA)
- BSA bovine serum albumin
- BSA may be present in the sperm composition in an amount of, less than about 5.0% (w/v); less than about 2% (w/v); less than about 1% (w/v); or about 0.1% (w/v).
- a protein source such BSA
- BSA protein source
- an alternative protein source or a protein substitute may be included in the sperm composition.
- the alternative protein source or protein substitute possess the advantageous effects of a typical protein source, such as BSA, in addition to the ability to inhibit the initiation of capacitation in a larger percentage of the cells in the sperm composition.
- Examples of a alternative protein sources includes human serum substitute supplement (SSS) (Irvine Scientific, Santa Ana, CA) and cholesterol enhanced BSA, while an example of a protein substitute includes a polyvinyl alcohol, such as for example, a low to medium viscosity polyvinyl alcohol generally of a molecular weight of about 30,000 to about 60,000. Generally, if included, these compositions will be present in the same amounts as disclosed above with respect to BSA, with the total albumin content of the buffer or buffered solution generally not exceeding about 5.0% (w/v).
- SSS human serum substitute supplement
- BSA cholesterol enhanced BSA
- an example of a protein substitute includes a polyvinyl alcohol, such as for example, a low to medium viscosity polyvinyl alcohol generally of a molecular weight of about 30,000 to about 60,000.
- these compositions will be present in the same amounts as disclosed above with respect to BSA, with the total albumin content of the buffer or buffered solution generally not exceeding about 5.0% (w/v).
- antibiotics may be included in the sperm composition in order to inhibit bacterial growth.
- exemplary antibiotics include, for example, tylosin, gentamicin, lincomycin, spectinomycin, Linco-Spectin® (lincomycin hydrochloride-spectinomycin), penicillin, streptomycin, ticarcillin, polymyxin B, or any combination thereof.
- the antibiotics may be present in a concentration of about 50 ⁇ g to about 800 ⁇ g per ml of semen, regardless of whether the semen is neat, buffered, or contains additional substances, such as for example, any of the additives mentioned herein.
- the Certified Semen Services (CSS) and National Association of Animal Breeders (NAAB) have promulgated guidelines regarding the use of antibiotics with respect to sperm collection and use.
- a growth factor may be added to the sperm composition in order to help maintain the viability of the sperm.
- growth factors include, for example, transforming growth factors ("TGF"), such as, for example, TGFP-l and TGFP-2, and insulin-like growth factors ("IGF"), such as for example, IGF-1.
- TGF may be present in the sperm composition in the form of TGFP-l in a concentration of about O.lng/L to about l( ⁇ g/L or as TGFP-2 in a concentration of about O.lng/L to about 200ng/L
- IGF may be present in the sperm composition in the form of IGF-1 in a concentration of about 0.1 ng/L to about 50 ⁇ g/L.
- the use of such growth factors is well known in the art and is disclosed, for example, in U.S. Patent Application Publication No. 2003/0157473, the content of which is hereby incorporated herein by reference.
- the collection fluid comprises sperm at a concentration of 200 x 10 7 cells/ml or less; 100 x 10 7 cells/ml or less ;500 x 10 6 cells/ml or less; 400 x 10 6 cells/ml or less; 300 x 10 6 cells/ml or less; 200 x 10 6 cells/ml or less; 180 x 10 6 cells/ml or less; 160 x 10 6 cells/ml or less; 120 x 10 6 cells/ml or less; 100 x 10 6 cells/ml or less; or 50 x 10 6 cells/ml or less.
- the staining solution comprises 0.01-3 mg of magnetic particles per 100 million sperm; 0.1-2 mg of magnetic particles per 100 million sperm; 0.1-2 mg of magnetic particles per 100 million sperm; 0.2-1.8 mg of magnetic particles per 100 million sperm; 0.5-1.6 mg of magnetic particles per 100 million sperm; 0.7-1.5 mg of magnetic particles per 100 million sperm; 1.0-1.4 mg of magnetic particles per 100 million sperm; 1.1-1.3 mg of magnetic particles per 100 million sperm; or 1.125 mg of magnetic particles per 100 million sperm.
- the sperm may be used, for example, in a staining process, a sorting process, or a fertilization process. If magnetic particles are used in the collection fluid, that may be removed prior to further processing. It is contemplated that any such further use and/or processing of the sperm may utilize magnetic particles.
- a process of staining sperm typically comprises the formation of a staining solution containing intact viable sperm and a dye, sometimes referred to as a label.
- the magnetic particles may be contacted with the sperm to form a sperm composition, and then the sperm composition contacted with a DNA selective dye to form the staining solution.
- a DNA selective dye may be added to a magnetic particles to form a staining solution, with sperm subsequently added to the staining solution.
- the sperm source may be neat semen, or alternatively, a sperm- containing semen derivative obtained by centrifugation or the use of other means to separate semen into fractions.
- the pH of the staining solution may be maintained at any of a range of pHs; typically this will be in the range of about 5.0 to about 9.0, or in the range of 5.5 to 7.8.
- the staining solution may be maintained at a slightly acid pH, i.e., from about 5.0 to about 7.0.
- the pH is from about 6.0 to about 7.0; from about 6.0 to about 6.5; about 6.2, about 6.5; about 6.6; about 6.7; about 6.8; about 6.9; or about 7.0.
- the staining solution may be maintained at a slightly basic pH, i.e., from about 7.0 to about 9.0.
- the pH is about 7.0 to about 8.0; about 7.0 to about 7.5; about 7.0; about 7.1; about 7.2; about 7.3; about 7.35; about 7.4; or about 7.5.
- the staining solution may be formed by using one or more UV or visible light excitable, DNA selective dyes as previously described in U.S. Patent No. 5,135,759 and WO 02/41906, the contents of each of which are hereby incorporated herein by reference.
- Exemplary UV light excitable, selective dyes include Hoechst 33342 and Hoechst 33258.
- Exemplary visible light excitable dyes include SYBR-14 and bisbenzimide-BODIPY® conjugate 6- ⁇ [3-((2Z)-2- ⁇ [1- (difluoroboryl)-3 ,5 -dimethyl- 1 H-pyrrol-2yl] methylene ⁇ -2H-pyrrol-5 -yl)propanoyl] amino ⁇ -N- [3- (methyl ⁇ 3- [( ⁇ 4- [6- (4-methylpiperazin-l-yl) -lH,3'H-2,5'bibenzimidazol-2'- yl]phenoxy ⁇ acetyl)amino]propyl ⁇ amino)propyl]hexanamide (“BBC”) described in WO
- Each of these dyes may be used alone or in combination; alternatively, other cell permeant UV and visible light excitable dyes may be used, alone or in combination with the aforementioned dyes, provided the dye does not detrimentally affect the viability of the sperm to an unacceptable degree when used in concentrations which enable sorting or enrichment as described elsewhere.
- the staining solution may also comprise a dye quencher in addition to a DNA selective dye.
- Staining protocols for sex sorting, or even bulk sorting, sperm typically rely upon the inclusion of F&DC red food dye No. 40 ("red food dye No. 40" or “red 40") and/or yellow food dye No. 4 as quenching dyes.
- the maximal absorbance wavelengths of these quenching dyes overlaps the maximal emissions wavelengths of fluorescent dyes, including Hoechst 33342 when bound to nuclear or chromosomal DNA. Because red food dye No. 40 and yellow food dye No.
- the staining solution may be formed using fluorescent polyamides, and more specifically polyamides with a fluorescent label or reporter conjugated thereto. Such labels will fluoresce when bound to nucleic acids.
- polyamides with a fluorescent label or reporter attached thereto include, for example, those disclosed in Best et al, Proc. Natl. Acad. Sci. USA, 15 100(21): 12063-12068 (2003); Gygi, et al, Nucleic Acids Res., 30(13): 2790-2799 (2002); U.S. Patent No. 5,998,140; U.S. Patent No. 6,143,901; and U.S. Patent No. 6,090,947, the content of each of which is hereby incorporated herein by reference.
- Fluorescent nucleotide sequences may also be used to label the sperm. Such nucleotide sequences fluoresce when hybridized to a nucleic acid containing a target or complementary sequence, but are otherwise nonfluorescent when in a non-hybridized state. Such oligonucleotides are disclosed, for example, in U.S. Patent Application Publication No.
- Sex specific antibodies may also be used to label the sperm in a staining solution.
- a sex specific antibody may be conjugated with a fluorescent moiety (or equivalent reporter molecule). Because the antibody binds to antigens present on only an X chromosome-bearing or, alternatively, a Y chromosome-bearing cell, such cells can be selectively identified based upon their fluorescence (versus the nonfiuorescence of an unlabeled cell).
- more than one sex specific antibody, each antibody having a different fluorescent moiety attached thereto may be used simultaneously. This allows for differentiation of X chromosome-bearing and Y chromosome-bearing cells based upon the differing fiuorescence of each.
- Luminescent, color-selective nanocrystals may also be used to label sperm in a staining solution.
- quantum dots these particles are well known in the art, as demonstrated by U.S. Patent No. 6,322,901 and U.S. Patent No. 6,576,291, each of which is hereby incorporated herein by reference.
- These nanocrystals have been conjugated to a number of biological materials, including for example, peptides, antibodies, nucleic acids, streptavidin, and polysaccharides, (see, for example, U.S. Patent Nos.
- the staining solution comprises sperm at a concentration of 500 x 10 6 cells/ml or less; 400 x 10 6 cells/ml or less; 300 x 10 6 cells/ml or less; 200 x 10 6 cells/ml or less; 180 x 10 6 cells/ml or less; 160 x 10 6 cells/ml or less; 120 x 10 6 cells/ml or less; 100 x 10 6 cells/ml or less; or 50 x 10 6 cells/ml or less.
- the staining solution comprises 0.01-3 mg of magnetic particles per 100 million sperm; 0.1-2 mg of magnetic particles per 100 million sperm; 0.1-2 mg of magnetic particles per 100 million sperm; 0.2-1.8 mg of magnetic particles per 100 million sperm; 0.5-1.6 mg of magnetic particles per 100 million sperm; 0.7-1.5 mg of magnetic particles per 100 million sperm; 1.0-1.4 mg of magnetic particles per 100 million sperm; 1.1-1.3 mg of magnetic particles per 100 million sperm; or 1.125 mg of magnetic particles per 100 million sperm.
- the concentration of the DNA selective or of any other type of dye in the staining solution is a function of a range of variables which include the permeability of the cells to the selected dye, the temperature of the staining solution, the amount of time allowed for staining to occur, the concentration of sperm, and the degree of enrichment desired in the subsequent sorting or enrichment step.
- the dye concentration is preferably sufficient to achieve the desired degree of staining in a reasonably short period of time without substantially detrimentally affecting sperm viability.
- the concentration of Hoechst 33342, Hoechst 33258, SYBR-14, or BBC in the staining solution will generally be between about ⁇ . ⁇ and about 1.0M; from about ⁇ . ⁇ to about 1000 ⁇ ; from about ⁇ to about 500 ⁇ ; from about 200 ⁇ to about 500 ⁇ ; or from about 300 ⁇ to about 450 ⁇ . Accordingly, under one set of staining conditions, the concentration of Hoechst 33342 is about 350 ⁇ . Under another set of staining conditions, the concentration of Hoechst 33342 is about 400 ⁇ . Under still another set of staining conditions the concentration is about 450 ⁇ .
- the concentration of a fluorescent polyamide such as for example, those described in U.S. Application Publication No. 2001/0002314, will generally be between about ⁇ . ⁇ and about ImM; about ⁇ to about ImM; about 5 ⁇ to about ⁇ ; or about 10 ⁇ .
- the staining solution may also contain additives to enhance sperm quality.
- additives include one or more OSRs, an antibiotic, a growth factor or a composition which regulates oxidation/reduction reactions intracellularly and/or extracellularly as discussed above with respect to cell sample collection. These additives may be added to the collection fluid in accordance therewith.
- the staining solution may be maintained at any of a range of temperatures; typically, this will be within a range of about 4°C to about 50°C.
- the staining solution may be maintained at a relatively low temperature, i.e., a temperature of about 4°C to about 30°C; in this embodiment, the temperature is about 20°C to about 30°C; from about 25°C to about 30°C; or about 28°C.
- the staining solution may be maintained within an intermediate temperature range, i.e., a temperature of about 30°C to about 39°C; in this embodiment, the temperature is at about 34°C to about 39°C; about 35°C; or about 37°C.
- the staining solution may be maintained within a relatively high temperature range, i.e., a temperature of about 40°C to about 50°C; in this embodiment, the temperature is from about 41°C to about 49°C; from about 41°C to about 45°C; from about 41°C to about 43°C; or about 41°C.
- Selection of a preferred temperature generally depends upon a range of variables, including for example, the permeability of the cells to the dye(s) being used, the concentration of the dye(s) in the staining solution, the amount of time the cells will be maintained in the staining solution, and the degree of enrichment desired in the sorting or enrichment step.
- Uptake of dye by the sperm in the staining solution is allowed to continue for a period of time sufficient to obtain the desired degree of DNA staining. That period is typically a period sufficient for the dye to bind to the DNA of the sperm such that X and Y chromosome-bearing sperm may be sorted or enriched based upon the differing and measurable fluorescence intensity between the two. Generally, this will be no more than about 24 hours; no more 30 than about 10 hours; no more than about 2 hours; no more than about 90 minutes; no more than about 60 minutes; or from about 5 minutes to about 60 minutes. In a particular embodiment, the period is about 30 minutes or about 55 minutes.
- the length of the staining period and the temperature at which staining occurs are related such that the longer the period of staining, the lower the temperature of staining temperature may be.
- the staining may occur at a relatively low temperature and for a period of about 3 hours to about 24 hours.
- the staining may occur at an intermediate temperature and for a period of about one half hour to about 3 hours.
- staining may occur at a relatively high temperature and for a period of about 10 minutes to about 90 minutes.
- staining may occur at a temperature of about 4°C for a period of about 24 hours.
- staining may occur at a temperature of about 18°C for a period of about 4 hours.
- staining may occur at a temperature of about 41°C for a period of about 30 minutes. In another embodiment, staining may occur at a temperature of about 35°C for a period of about 55 minutes. Accordingly, in one embodiment, a staining solution is formed comprising magnetic particles, sperm and a dye in a concentration from about ⁇ to about 450 ⁇ , and the staining mixture is held for a period of time at a temperature of about 28°C; about 35°C; or about 41°C. In another embodiment, the period of time is about 30 minutes; about 55 minutes; or about 3 hours.
- magnetic particles are used in the staining solution, it is contemplated that such magnetic particles may be removed prior to any further processing steps. Alternatively, in another embodiment the magnetic particles may remain in the staining solution for further processing including sorting on a flow cytometer.
- Some embodiments include use of one or more OSRs as pre-mixed components of the prepared buffers, extenders, stains, catch fluids, and/or cryo-extenders used in the sex sorting procedure.
- a quenching dye without the need for a DNA staining dye may be required, in which case the OSR will only be present with the quenching dye to form the stained sample.
- Commonly used and well known sorting methods include flow cytometry systems, as exemplified by and described in U.S. Patent Nos. 5,135,759, 5,985,216, 6,071,689, 6,149,867, and 6,263,745; International Patent Publications WO 99/33956 and WO 01/37655; and U.S. Patent Application Serial
- the sperm are introduced into the nozzle of a flow cytometer in a sample fluid.
- the sample fluid may comprise magnetic particles and the stained sperm.
- sex sorting of sperm may be accomplished using any process or device known in the art for cell analysis, sorting and/or population enrichment including but not limited to use of a flow cytometer or use of a microfluidic chip, and encompasses techniques for physically separating X and Y bearing sperm from each other, as with droplet sorting and fluid switching sorting, and techniques for gender enrichment in which sperm bearing the undesired sex chromosome are killed, immobilized, or otherwise rendered infertile, such as by use of laser ablation/photo-damage techniques.
- devices used with the invention determine a property of sperm based on fluorescence emitted by the sperm when passed before a source of illumination such as a laser beam.
- a source of illumination such as a laser beam.
- Other properties include but are not limited to viability, motility, intact or damaged membranes, genetic defects, the presence or absence of specific genes or gene markers, morphology and fertility.
- the user decides the property or properties the device will analyze and select for, referred to as a property, or properties, of interest.
- the devices used with the invention can analyze sperm and then select the sperm having the property of interest by, for example, photo-damaging/laser ablating the sperm having the property of interest.
- the devices used with the invention can photo-damage/laser ablate the sperm without the property of interest, leaving the sperm having the property of interest in tact.
- the devices of invention can select sperm having the property of interest by isolating the sperm having the property of interest, by for example, separating, or sorting, the sperm having the property of interest from sperm without the property of interest.
- Devices that may be used with the invention include but are not limited to those disclosed above as well as in US Patent Application Publication No. US 2008/0153087 at paragraphs 23-87; paragraphs 99-148; and Figures 1-5; and in US Patent No. 8,206,987 at column 28, line 17 to column 93, line 35; column 126, line 54 to column 130, line 3; and Figures 135-138; the disclosures of which are
- sheath fluid is used to surround the stream of sample fluid as it travels through a flow cytometer or micro fluidic chip.
- the sheath fluid may be introduced into a nozzle of a flow cytometer using pressurized gas or by a syringe pump.
- the pressurized gas is often carbon dioxide or nitrogen.
- a stream containing sperm to be analyzed may be comprised of a sample fluid and a sheath fluid, or a sample fluid alone.
- sample fluid or sheath fluid may also contain an additive, such as, one or more OSRs, an antibiotic or a growth factor, as discussed above with respect to cell sample collection.
- an additive such as, one or more OSRs, an antibiotic or a growth factor, as discussed above with respect to cell sample collection.
- OSRs oxygen species
- an antibiotic or a growth factor as discussed above with respect to cell sample collection.
- Each of these additives may be added to either fluid in accordance therewith.
- a sheath fluid comprises Tris(hydroxymethylaminomethane), sodium-citrate dihydrate and citric acid anhydrous.
- Tris(hydroxymethylaminomethane), sodium-citrate dihydrate and citric acid anhydrous To prepare this low sugar sheath fluid, regardless of the intended volume of sheath fluid desired, the entire quantity of Tris and sodium- citrate are mixed with approximately 95% of the desired volume of ddH 2 0. Three quarters of the citric acid is also concurrently added. A titration with the remaining quantity of citric acid is performed to reach a specific pH of 6.80. After pH adjustment, ddH 2 0 is added until an osmolarity of 300 mOsm is obtained. One or more OSRs may also be added to this sheath fluid, typically in the range of 0.01 to 5.0 mg/ml.
- Figure 1 illustrates, in schematic form, part of a flow cytometer used to sort a sperm composition to form one or more subpopulations, the flow cytometer being generally referenced as 10.
- sex sorting is taking place so the subpopulations are X-chromosome bearing sperm and Y-chromosome bearing sperm.
- the flow cytometer 10 of Figure 1 can be programmed by an operator to generate two charged droplet streams, one containing X-chromosome bearing sperm, charged positively, 12, one containing Y-chromosome bearing sperm, charged negatively 13 while an uncharged undeflected stream of dead cells 14 simply goes to waste.
- An operator may also choose to program the flow cytometer in such a manner, that both the X- and Y-chromosome bearing sperm are collected using a "high purity sort” (in other words only live X- and Y-chromosome bearing sperm are collected) or to program the flow cytometer to collect both the X- and Y-chromosome bearing sperm using an "enriched sort” (in other words it will collect droplets containing live cells that were not previously sorted and excluding all initial dead cells again by the use of Boolean Gate logic available with the computer that controls the flow cytometer).
- the Boolean Gate logic can also be used to collect only one of either the X- or Y-chromosome bearing sperm.
- a stream of sperm under pressure is deposited into the nozzle 15 from the sperm source 11 in a manner such that they are able to be coaxially surrounded by a sheath fluid supplied to the nozzle 15 under pressure from a sheath fluid source 16.
- An oscillator 17 which may be present can be very precisely controlled via an oscillator control mechanism 18, creating pressure waves within the nozzle 15 which are transmitted to the coaxially surrounded sperm stream as it leaves the nozzle orifice 19.
- the exiting coaxially surrounded sperm stream 20 could eventually and regularly form droplets 21.
- the charging of the respective droplet streams is made possible by the cell sensing system 22 which includes a laser 23 which illuminates the nozzle exiting stream 20, and the light emission of the fluorescing stream is detected by a sensor 24.
- the information received by the sensor 24 is fed to a sorter discrimination system 25 which very rapidly makes the decision as to whether to charge a forming droplet and if so which charge to provide the forming drop and then charges the droplet 21 accordingly.
- a characteristic of X-chromosome bearing sperm is that they absorb more fluorochrome dye than Y-chromosome bearing sperm because of the presence of more DNA, and as such, the amount of light emitted by the laser excited absorbed dye in the X-chromosome bearing sperm differs from that of the Y-chromosome bearing sperm and this difference communicates to the sorter discrimination system 25 the type of charge to apply to the individual droplets which theoretically contain only a single X- or Y-chromosome bearing sperm. Dead cells (or those about to die) typically absorb the quenching dye which is communicated to the sorter
- the charged or uncharged droplet streams then pass between a pair of electrostatically charged plates 26, which cause them to be deflected either one way or the other or not at all depending on their charge into respective collection vessels 28 and 29 to form respectively a gender enriched population of X-chromosome bearing and a gender enriched Y-chromosome bearing sperm having a DNA selective dye associated with their DNA.
- the uncharged non- deflected sub -population stream containing dead cells (or those about to die) go to the waste container 30.
- the cells of a sperm composition may be sorted or enriched using laser steering. This is often referred to as optical trapping or holographic optical trapping.
- optical trapping or holographic optical trapping.
- tightly focused laser light such as, for example, light focused by a microscope lens, will have a steep intensity gradient.
- Optical traps use the gradient forces of a beam of light to trap particles based upon the dielectric constant of the beam. To minimize its energy, a particle having a dielectric constant greater than the surrounding medium will move to a region of an optical trap where the electric field is highest.
- Such devices and methods are described, for example, in WO 2004/012133, U.S. Patent No. 6,416,190 and related applications and patents, the content of each of which is hereby incorporated herein by reference.
- the cells of the sperm composition may be sorted accordingly into separate populations, wherein the spermatozoa of the populations comprises a certain percent X chromosome bearing or Y chromosome bearing sperm.
- Laser ablation/photo damage or fluid switching may also be used to create gender enriched
- any of the steps of the cell sorting process may be carried out within a temperature range selected from the group consisting of about 5°C to about 15°C; about 15°C to about 20°C; about 20°C to about 25°C; about 25°C to about 30°C; about 30°C to about 35°C; about 35°C to about 40°C and about 40°C to about 45°C.
- sorted or gender enriched sperm of the invention may comprise at least about 65% X chromosome bearing or Y chromosome bearing sperm, at least about 70% X chromosome bearing or Y chromosome bearing sperm, at least about 75% X chromosome bearing or Y chromosome bearing sperm, at least about 80% X chromosome bearing or Y chromosome bearing sperm, at least about 85% X chromosome bearing or Y chromosome bearing sperm, at least about 90% X chromosome bearing or Y chromosome bearing sperm, at least about 95% X chromosome bearing or Y chromosome bearing sperm, at least about 98% X chromosome bearing or Y chromosome bearing sperm, or at least about 99% X chromosome bearing or Y chromosome bearing sperm.
- the sorted cells are collected in a vessel that contains a catch media.
- the purpose of the catch media includes providing a fluid support for the cells.
- the catch media may comprise magnetic particles.
- the catch media may further comprise any of the additives as discussed above with respect to cell sample collection, including but not limited to one or more OSRs, cryoprotectants, sterols, lipids, fatty acids and protein sources. If included in the catch media, the sterols, lipids, and fatty acids may be, for example, cholesterol.
- Exemplary protein sources include milk (including heat homogenized and skim), milk extract, egg yolk, egg yolk extract, soy protein and soy protein extract.
- Such proteins may be used in a concentration from about 1% (v/v) to about 30% (v/v), preferably from about 10%> (v/v) to about 20%) (v/v) , and more preferably about 10%> (v/v).
- the catch media may also contain additives such as, an antibiotic, a growth factor or one or more OSRs, as discussed above with respect to cell sample collection.
- additives such as, an antibiotic, a growth factor or one or more OSRs, as discussed above with respect to cell sample collection.
- Each of these additives may be added to the catch media in accordance therewith.
- a catch media is prepared by adding the appropriate amount of egg yolk to media comprising Tris(hydroxymethylaminomethane), sodium citrate dehydrate and citric acid anhydrous, mixing and then allowing the mixture set overnight at 5°C. The following day the mixture is centrifuged at 5000g for 1.5h. After centrifugation, the top layer of the supernatant is discarded, and the remaining supernatant, which comprises the low sugar catch media, is collected.
- One or more OSRs may also be added to the catch media, typically in the range of 0.01 to 5.0 mg/ml. The catch media should then be stored at 5°C until use.
- the catch media can be frozen prior to storage and/or shipping. It should be understood that magnetic particles may be added during any of the aforementioned steps for preparing catch media including prior to use, prior to freezing or subsequent to thawing of the media.
- Gender enriched sperm may be collected into a vessel containing or coated with a cryoextender comprising magnetic particles, a cryoprotectant and optionally, any of the additives as discussed above with respect to sperm collection. In one embodiment, prior to
- the magnetic particles are removed from the catch media or the cryoextender prior to further processing or cryopreservation of the gender enriched sperm.
- the sperm Once the sperm have been sorted and caught in collection vessels, they may be used for inseminating female mammals. This can occur almost immediately, requiring little additional treatment of the sperm. In such an instance, the sperm may be stored in their current state for a period of time necessary to, for example, transport them to the location where the insemination is to take place. The sperm may, therefore, be stored and transported in, for example, the catch media.
- the sperm may be concentrated to a density appropriate for the particular mammalian species, for example, a density of about 10 x 10 6 sperm/ml to about 120 x 10 6 sperm/ml, in a magnetic particles and subsequently stored and transported.
- the selected density depends upon factors such as those discussed below with respect to fertilization, including the species of mammal from which the sperm were obtained.
- Such a range of densities based upon the species of mammal from which the sperm were obtained are well known to those of skill in the art.
- the sperm may also be cooled or frozen for use at a later date. In such instances, the sperm may benefit from the addition of a cryoextender to minimize the impact upon viability or post-thaw motility as a result of cooling or freezing.
- a protein source may be added to provide support to the sperm. Examples of common protein sources include milk (including heat homogenized and skim), milk extract, egg yolk, egg yolk extract, soy protein and soy protein extract. Such proteins may be found in a concentration from about 3% (v/v) to about 30% (v/v); from about 10%> (v/v) to about
- a cryoprotectant is preferably included in the cryoextender to lessen or prevent cold shock or to maintain fertility of the sperm.
- Numerous cryoprotectants are known in the art. Selection of a cryoprotectant suitable for use with a given extender may vary, and depends upon the species from which the sperm to be frozen were obtained. Examples of suitable
- cryoprotectants include, for example, glycerol, dimethyl sulfoxide, ethylene glycol, propylene glycol, trehalose, Triladyl®, and combinations thereof. If included, generally, these
- cryoprotectants are present in the cryoextender in an amount, by percent volume, of about 1-5%; 5%; about 5 to 10%; about 10%; about 10 to 20%; about 16.7%; about 20%; about 20 to 30%; or about 30 to 40%.
- the cryoextender may also contain additives as discussed above with respect to cell sample collection, including but not limited to an antibiotic, a growth factor, or one or more OSRs. Each of these additives may be added to the cryoextender in accordance therewith.
- the following method of freezing porcine sperm can be used with the invention, but is presented by way of example only— any suitable cryopreservation method known in the art can be used.
- 50 ml tubes containing the sex sorted sperm (each with 20 million cells) can be divided into tubes of 15 ml, with approximately 12 ml of a sex-select sperm sample in each tube, each containing approximately 10 million sex sorted sperm.
- Theses tubes can be centrifuged at 3076 g at 21°C for 4 minutes. The supernatant decanted, and the pellet can remain with some of the supernatant in approximately 50 ⁇ .
- a first cooling medium that may comprise a solution of 20% egg yolk and/or lactose can then be added at room temperature. The motility of the sperm can then be checked.
- the tubes can be taken to a programmable temperature control machine (PolyScience - MiniTube) or can be manually handled to decrease the temperature from about 21°C to about 5°C over a period of about 2 hours.
- a freezing medium is added to the cells, which may comprise egg-yolk, lactose, glycerol and EquexPasteStem, or may just comprise a cryoprotectant such as glycerol, or the cryoprotectant with an osmotic stabilizer which is previously cooled to 5°C is added to the samples.
- the sex sorted sperm composition can be placed in artificial insemination straws, and the straws then exposed to liquid nitrogen vapors (approximately 4 cm from the liquid nitrogen) for a short period of time (e.g. 10 minutes) or cryopreserved in programmable freezer and then placed directly into the liquid nitrogen for long term
- straws When gender enriched sperm compositions are ready for use, straws can be unfrozen by thawing/warming the straws (e.g. place in a water bath set at about 37°C for about 1 minute or 50° for 20 seconds). Post-thaw, motility and viability of the sperm can then be analyzed at 30, 90 and/or 150 minutes for standard comparisons. Magnetic particles can be added to the thawed sperm composition and then subsequently removed prior to any further processing or use in AI.
- the sperm may be stored for a period of time.
- the period of storage is dependent upon several factors, including for example, the temperature at which the cells are stored, the number of cells within the storage container, whether the sperm are sorted or unsorted or have been previously been subjected to other processes such as cryopreservation, the method of fertilization for which the cells will be used, and the female mammal being fertilized.
- the sperm may be stored for several hours, such as for example, 2, 4, 8, 12, or 24 hours; for several days, such as for example 1, 2, 3, 4, 5, 6, or 7 days; several weeks, such as for example, 1, 2, 3, or 4 weeks; or several months, such as for example, 1, 2, or 3 months.
- sperm may be stored for several hours to several days at a temperature of about 0°C to about 30°C; for several days to several weeks at a temperature of about -4°C to about 5°C; and for several weeks to several months at a temperature of about -196°C (in liquid nitrogen vapor) to about -4°C.
- a sample can be held at a temperature of 0-39°C (typically 16-17°C) for between about 12 hours to about 18 hours while it is being shipped from the collection point to the point of further processing or use.
- the sample can be held at a temperature of 0-39°C (typically 16- 17°C) for more than 18 hours.
- magnetic particles are added to the storage medium and then subsequently removed either before or after the storage period, e.g., prior to use in AI. Magnetic particles may be added and removed to a sperm composition after the storage period and prior to use as well.
- the sperm whether sorted or unsorted, may be stored at a range of different
- a storage temperature is dependent upon several factors, such as for example, the length of time for which the sperm will be stored, the concentration of sperm within the storage container, whether the sperm are sorted or unsorted, the method of fertilization for which the sperm will be used, and the female being fertilized. All of these factors affect the number of sperm that will remain viable during the storage period. By way of example, generally the greater the length of time for which the sperm may be stored, the lower the temperature at which the sperm may be stored. In certain species, a decrease in temperature generally permits a greater percentage of the stored sperm to remain viable over a longer period of time. In other species, such as with porcine sperm, this may not be true.
- sperm may be stored at a temperature of about -196°C to about 30°C.
- sperm may be stored at a relatively low storage temperature, i.e., a temperature range of about -196°C to about -4°C; in this embodiment, the temperature is typically from about - 12°C to about -4°C; from about -10°C to about -4°C; or about -4°C.
- the sperm may be stored at an intermediate storage temperature, i.e., a temperature range of about -4°C to about 5°C; in this embodiment, the temperature is typically at about -3°C to about 5°C; about 0°C to about 5°C; or about 5°C.
- the sperm may be stored at a moderately high storage temperature, i.e., a temperature range of about 5°C to about 30°C; in this embodiment, the temperature is typically from about 10°C to about 25°C; from about 12°C to about 23°C; from about 15°C to about 20°C; or about 18°C.
- a moderately high storage temperature i.e., a temperature range of about 5°C to about 30°C; in this embodiment, the temperature is typically from about 10°C to about 25°C; from about 12°C to about 23°C; from about 15°C to about 20°C; or about 18°C.
- the sperm composition may be stored in a range of different containers. While the containers may vary in size, generally suitable containers will be capable of containing the sperm composition; that is to say, the containers will be constructed of a material that is not susceptible to leaking or deterioration as a result of contact with fluids generally, and sperm compositions specifically, regardless of whether such contact occurs on the inside or outside of the container. Examples of suitable containers include, for example, flasks, beakers, test tubes, ampules, and other such containers that are generally constructed of glass, plastic, or other similar materials. In a particular embodiment, the container is of a type of construction that is used in the
- Such elongated containers may generally have a length to diameter ratio of about 1000: 1 to about 100: 1; a length to diameter ratio of about 900: 1 to about 200: 1; a length to diameter ratio of about 800: 1 to about 300: 1; a length to diameter ratio of about 700: 1 to about 400: 1; a length to diameter ratio of about 600: 1 to about 400: 1; a length to diameter ratio of about 500: 1 to about 400: 1; and in one particular embodiment, a length to diameter ratio of about 450: 1.
- Such elongated containers may generally have a volume of 10 about O.lcc to about lOOcc, the volume of the container selected to be used being based upon the species of mammal from which the semen was collected.
- the volume of such elongated containers may be from about O.lcc to about 0.7cc, preferably a volume of about 0.2cc to about 15 0.6cc, more preferably a volume of about 0.23cc to about 0.5cc, and most preferably a volume of about 0.3cc to about 0.4cc.
- the elongated container is what is commonly referred to in the artificial insemination industry as a straw, having a volume of about 0.23cc and a length to diameter ratio of about 133: 1.
- the elongated container is what is commonly referred to in the artificial insemination industry as a straw, having a volume of about 0.5cc and a length to diameter ratio of about 67: 1.
- containers of these volumes are used for the storage of bovine sperm.
- the volume of the elongated containers may be from about lcc to about lOOcc; about lOcc to about 75cc; about 15cc to about 50cc; about 20cc, to about 40cc; or a volume of about 25cc to about 30cc.
- the elongated container is what is commonly referred to in the artificial insemination industry as a straw, having a volume of about 25 cc and a length to diameter ratio of about 445 : 1.
- containers of this volume are used for the storage of porcine sperm.
- the advantage of storing the sperm composition in a straw is that the composition may remain stored therein until it is to be used for insemination of a female, at which time the contents of the straw may be placed into the uterus of a female.
- Another aspect of the present invention is the fertilization of an egg or insemination of a female, generally employing the novel process for processing and/or storing spermatozoa as described above.
- the sperm composition may be used to inseminate a female.
- Insemination may be performed according to any of a number of ART methods well known to those of skill in the art. These methods include, for example, artificial insemination, including standard artificial insemination, deep uterine insemination and laparoscopic insemination, and other methods well known to those of skill in the art.
- a sperm composition comprising magnetic particles and one or more OSRs may be used to inseminate a female, such as for example, by artificial insemination.
- the sperm composition may be in an elongated container for use in the
- the sperm composition may be used to fertilize an egg, and more particularly, an egg in vitro, such as for example, by microinjection, including intracytoplasmic sperm injection (ICSI), and other methods well known to those in the art.
- the fertilized egg may thereafter be introduced into the uterus of a female by any of a number of means well known to those of skill in the art, such as for example embryo transplant.
- zygotes and/or embryos from artificially inseminated females can be recovered and then cultured and/or cryopreserved/vitrified.
- Insemination of a female mammal or fertilization of an egg in vitro (followed by introduction of the fertilized egg into the uterus of a female) using a sperm composition may occur shortly after formation of the sperm composition, such as for example, within about 120 hours; within about 96 hours; within about 72 hours; within about 48 hours, and in a particular embodiment, within about 24 hours after formation of the sperm composition.
- the sperm compositions may not have been cryopreserved prior to insemination of a female or fertilization of an egg in vitro (i.e., the composition is fresh or comprises fresh sperm) instead it may have been refrigerated at temperatures of about 4°C to about 25°C; about 10°C to about 25°C; about 15°C to about 20°C; or about 18°C.
- the sperm composition may be cryopreserved and then thawed prior to insemination of a female or fertilization of an egg in vitro (i.e., the dispersion is frozen/thawed or comprises frozen/thawed sperm).
- cryopreserved sperm composition will be thawed immediately, such as, for example, within about 15 minutes, before insemination of a female or fertilization of an egg in vitro.
- cryopreserved dispersion may be thawed over a period of time or thawed and subsequently stored for a period of time, such as for example less than about 5 days; less than about 2 days; less than about 1 day; or less than about 12 hours.
- Magnetic cores may be fabricated such as by co-precipitation of Fe30 4 with Fe 2 03 so that the magnetic susceptibility of the particles in a chosen magnetic field may be sufficiently high to provide rapid separation of magnetically labeled cells from non-labeled cells.
- the core may be comprised of any magnetic material; possible non-limiting examples include: (1) ferrites such as magnetite, zinc ferrite, or manganese ferrite; (2) metals such as iron, nickel, or cobalt; and (3) chromium dioxide.
- the iron cores are comprised of magnetite (Fe30 4 ).
- the core may be extended to include substances such as other iron oxide based nanoparticle materials including composites having the general structure MFe 2 0 4 (where M may be Co, Ni, Cu, Zn, Mn, Cr, Ti, Ba, Mg, or Pt).
- M may be Co, Ni, Cu, Zn, Mn, Cr, Ti, Ba, Mg, or Pt.
- a reaction chamber containing 400 mL of dH 2 0 in a water kettle was warmed to 60° C.
- 23.4 g of FeCl 3 .6H 2 0 and 8.6 g of FeCl 2 or the like was added and the mixture was stirred under N 2 gas.
- 30 mL of 25% NH 3 .H 2 0 was added and mixing was continued under N 2 gas.
- the orange salt mixture turned to a dark brown/black solution.
- the magnetically collected ferro fluid 800 mL of dH 2 0 was added, swirled, and the magnetic collected process was repeated. The washing process was repeated four times to remove substantially all residual NH 3 .H 2 0 and any nonmagnetic particles.
- the final wash step may include a solution of 800 mL 0.02 M NaCl in dH 2 0 or the like.
- the collected iron core sizes were between approximately 3 and approximately 10 nm.
- the final outer layer may comprise a polymer coat that interacts with the aqueous environment and serves as an attachment site for proteins and ligands.
- Suitable polymers may include polysaccharides, alkylsilanes, biodegradable polymers such as, for example, poly(lactic acids) (PLA), polycaprolactone (PCL), and polyhydroxybutyrate -valerate (PHBV); composites, and polyolefms such as polyethylene in its different variants. More specifically, polysaccharide chains may include dextrans, arabinogalactan, pullulan, cellulose, cellobios, inulin, chitosan, alginates, and hyaluronic acid.
- Silicon containing compounds such as alkylsilanes may also be employed to encapsulate the magnetic core.
- Alkylsilanes suitable for embodiments of the described methods and processes may include but are not limited to, n-octyltriethoxysilane, tetradecyltrimethoxysilane, hexadecyltriethoxysilane, hexadecyltrimethoxysilane, hexadecyltriacetoxysilane,
- the ratio of iron to silicon containing compound coating may be approximately 0.2. In other embodiments, the ratio of iron to silicon containing compound coating may be greater than about 0.2, such as about 0.4 or 0.8, with a view toward completely coating the iron cores such that the iron cores may be removed from the cell suspension within the magnetic field.
- the ratio of iron to silicon containing compound coating may be less than 0.2. Indeed, the iron concentration divided by the silicon containing compound concentration may be from about 0.1 to about 1.
- a silicon containing compound may be used to encapsulate the iron cores.
- the iron core precipitate may be allowed to settle.
- 67.1 mg of the ferro fluid were added to 100 mL of 10% 2-(carbomethoxy)ethyltrimethoxysilane.
- 2- (carbomethoxy)ethyltrimethoxysilane is yet another example of a silicon containing compound that is suitable for use in the described methods and processes as a silicon containing compound coating.
- the pH was adjusted to 4.5 using >99.5%> glacial acetic acid, and the suspension was reacted at 70° C. for 2 h under N2 gas with vigorous mixing.
- the particles may be magnetically collected and washed with dH 2 0.
- the silane-coated magnetic nanoparticles may be suspended in 5 mL of 0.05 M 2-(N-morpholino)ethanesulfonic acid (MES) Buffer, TRIS Buffer, TALP buffer, or it may remain in the dH 2 0 until use for separation.
- the resuspension buffer may be at a pH that retains or creates a net negative zeta potential of the particles.
- Iron concentration may be determined using Inductively Couple Plasma-Optical Electron Spectroscopy (ICP-OES), and the iron concentration may be adjusted according to milligrams per milliliter needed for optimal dead cell removal.
- the particles may have an average hydrodynamic diameter of 300 nm, and need to be in a range of 300 to 1000 nm to stay suspended in solution so that maximum interaction between the cells and particles is achieved by keeping the particles in suspension and not settling out due to larger sizes.
- Coupling of proteins and ligands to the particle surfaces In the event that the surface of the particles needs to be treated and conjugated to a protein or antibody, the following methods may be used. Periodate treatment of dextran and other polymers are one method for the attachment of proteins due largely to the large number of reactive groups that are available for modification. Mild sodium periodate treatment may create reactive aldehyde groups by oxidation of adjacent hydroxyl groups or diols. Proteins, antibodies, streptavidin, and amino- modified nucleic acids may be added at high pH to allow amines to form Schiff bases with the aldehydes.
- the linkages may be subsequently reduced to stable secondary amine linkages by treatment with sodium borohydride or sodium cyanoborohydride, which may reduce unreacted aldehyde groups to alcohols.
- Another method of coupling proteins to the magnetic nanoparticles may be to create stable hydrazine linkages.
- a protein may be coupled to dextran using succinimidyl 4-hydrazinonicotinate acetone hydrazone (SANH; Solulink Inc, San Diego, Calif). The reaction may use five-fold less protein, and the resulting protein density may appear as high as with other methods.
- the SANH reagent may allow more efficient and gentle coupling of ligands to the dextran surface.
- Ligand attachment on silica-coated magnetic nanoparticles may be completed using (3-aminopropyl)triethoxysilane (APTS) to introduce amines on the particle surface while (3-mercaptopropyl)triethoxysilane (MPTMS) introduces SH groups.
- the heterobifunctional coupling agent (Succinimidyl 4-[N-maleimidomethyl]cyclohexane-l- carboxylate) may then be used to link thiols to the amines.
- amines on the particle surface may be linked to thiols on streptavidin molecules, and thiols on the particle surface may be linked to amines on streptavidin.
- the carboxylic acid functionalized silane may attach proteins and ligands through EDC chemistry.
- EDC Activation of COOH groups on Particle Surface Activation The silanized particles were re-suspended in 0.05 M MES buffer, collected magnetically, and the supernatant may be aspirated and discarded. Another 5 mL of MES buffer (0.05 M, pH 4.7-5.2) per 10 mg of iron was added to the particles and the suspension was vigorously shaken. Particles were magnetically collected, and the supernatant was aspirated and discarded. This step may be repeated two or so additional times. Frozen EDC was allowed to thaw at room temperature for 30 min. EDC (also known as ED AC or EDCI, l-ethyl-3 -(3 -dimethyl aminopropyl)
- carbodiimide commonly obtained as a hydrochloride, is a water soluble carbodiimide, which is typically employed at pH in the range between 4.0 and 6.0.
- EDC may be used as a chemical crosslinker for collagen, reacting with the carboxylic acid groups of the collagen polymer which may then bond to the amino group in the reaction mixture.
- concentrations, molarities, including but not limited to, 0.1 M to 1 M, and pH ranges from 10 to 4.7 may be used for protein conjugation to the various surfaces.
- the function of each antibody, protein and ligand optimizes at different pH ranges and molarities, as is known in the art (Hermanson, Bioconjugate Techniques, 2008).
- the particle pellet was added to 0.05M MES buffer, particles may be magnetically collected, and supernatant may be aspirated and discarded. This step may be repeated three or so times. 10 mg of protein, ligand or stain was suspended in 0.05M MES buffer and added to the particles so that the total labeling volume was about 5 mL per 10 mg of iron.
- a stoichiometric balance of 1 mg of protein, ligand, or stain per 1 mg of iron was used for the coupling reaction. Some experiments suggested that the best binding of dead or compromised cells is concentration dependent and may occur at about this concentration (with the above percentage variations applicable, of course).
- the range in antibody or protein used may include, but is not limited to, 0.125 mg to 5 mg of antibody per mg of iron. Tubes were shaken and placed on a laboratory rocker at room temperature for 24 h, and particles were magnetically collected. The supernatant was aspirated and discarded. Each particle suspension was suspended in 5 mL of MES buffer. To each tube, 5 mL of quenching solution (1M glycine, pH 8.0) was added and the tubes were shaken vigorously. Quenching solutions may include, but are not limited to, 2-mercaptoethanol, ethanolamine, glycine, UV exposure, size exclusion and magnetic collection. Each tube was placed on a laboratory rocker for 30 min. at room
- each particle suspension was suspended in a buffer for the particular cells, such as for sperm cells or other such cells, with a pH (6.0-8.0) and osmolality (250-350) suitable for optimal sperm or other cell viability such as but not limited to TRIS solution, Sodium Citrate solution, TEST solution, egg yolk-TRIS (pH 6.5-7.4), egg yolk-sodium citrate (pH 6.5-7.4), egg yolk-TEST (pH 6.5-7.6), milk extenders (pH 6.5-7.4), commercially available extenders marketed by IMV International, Maple Grove, Minn., USA and MiniTube GmbH, Vernona, Wis., USA and chemically defied media including but limited to TALP (pH 6.0-8.0) Tyrodes (pH 6.0-8.0) and Hepes BGM-3 (pH 6.0-8.0) so that the resultant working iron concentration was about 4 mg/mL as confirmed by Inductive Coupled Plasma-Optical Emission Spectroscopy (ICP-
- the particles may be advantageously on the order of about 300 nm so that interaction between the particles and that of the damaged or dead cells is maximized in solution. If particles are too large, such interaction may not occur due to the settling effect of the larger sized particles in solution. If particles are smaller than approximately 30 nm, they may either not be sufficiently magnetic and higher magnetic susceptibility core materials within a chosen magnetic energy field will have to be generated, or these small particles may contribute to nonspecific binding; that is, they may bind to viable cells as well as to dead and dying cells. If nonspecific binding relating to particle size is problematic, particle size may either be increased, or a blocking agent dependent upon the particular cells involved, such as nonfat dried milk or serum albumin for sperm, may be added to the labeling buffer solution to minimize such nonspecific binding.
- the surface charged particles are comprised of Fe30 4 coated with 2- (carbomethoxy)ethyltrimethoxysilane without further activation or functionalization.
- the ratio of iron to silicon containing compound coating is approximately 0.2.
- Lot 1 was the first batch and used for field trial; Lot 2A was similar to Lot 1 ; Lot 2B was made using less silane per concentration of iron cores that Lot 1 and Lot 2A; and Lot 3 was larger than Lot 2A and 2B combined and had a slightly larger load of iron per L. Also, Lot 3 was sonicated and compared to Lot 3 without sonication.
- Lot 3 represents a 6 fold scale up of the step of production of magnetite cores and 150 fold scale up from the step of silane coating of cores and magnetic recovery.
- the scale of Lot 3 produced -20 grams (iron content), which using lmg/160 million sperm results in sufficient particles to treat -3000 billion sperm. Assuming an average ejaculate of 10 billion sperm, approximately 300 ejaculates could be processed with 20 grams of magnetic particles.
- Lots 1 , 2A, 2B and 3 were compared for dead removal capacity and Post-Thaw quality control data (e.g., motility, percent intact acrosomes [PIA] and progressive motility).
- Post-Thaw quality control data e.g., motility, percent intact acrosomes [PIA] and progressive motility.
- PROCEDURE 1 Check volume, concentration, motility, morphology and pH of ejaculates from 5 bulls. Add antibiotics.
- Control - keep as it is
- Lot 1 - add lmg of Lot 1 particles for every 160 million sperm
- Lot 2A - add lmg of Lot 2A particles for every 160 million sperm
- Lot 2B - add lmg of Lot 2B particles for every 160 million sperm
- Lot 3 - add lmg of Lot 3 particles for every 160 million sperm
- Control - keep as it is
- Lot 3 particles add lmg of Lot 1 particles for every 160 million sperm
- control sample (320 mill sperm total)
- Treated samples will be treated with 3.6 mg magnetic particles in 300 of modified TALP, pH 7.4.
- Control samples will be treated with the same of modified TALP, pH 7.4 (without particles).
- the average %> sperm removed according to the NucleoCounter was 32%>. 14%> of cells were unaccounted for (when comparing NucleoCounter and flow cytometer data).
- control sample (320 mill sperm total)
- Treated samples will be treated with 3.6 mg magnetic particles in 300 of modified TALP, pH 7.4.
- Control samples will be treated with the same of modified TALP, pH 7.4 (without particles).
- Staining volume in modified TALP (20% Y6 with antioxidants), pH 7.4 and Hoechst 33342 will be 4mL. After 45 minutes of incubation at 34°C, samples divided in two: one will be used as control and the other will be treated with magnetic particles (each one will a total of 320 million sperm in 2mL).
- sperm concentrations will be determined in the treated and the control samples to quantify the % of total sperm (dead + unaccounted) removed by the particles and 2mL of red TALP will be added for dead sperm quenching.
- Data from individual sorter histograms (using production sorters) will provide results for the amount of dead sperm (with and without treatment) as well as flow cytometer performance. See results in Figures 20-22.
- Samples will be sex-sorted, frozen (5 straws per treatment for each bull) and sent to IVF trials. Standard post-thaw QC analysis will also be performed. See results in Figures 23 and 24.
- Ferrofluid (67.6 mgs) is added to 10% Carboxyethylsilanetriol sodium salt in water (35.5 mLs).
- the pH is adjusted with >99%> glacial acetic acid so that the pH reads 4.5.
- the suspension is reacted at 70°C for 2 hours with mixing (evaporate ⁇ l/2 of the volume).
- silane coated magnetic nanoparticles are resuspended in storage buffer (pH 7.4) at a known volume.
- a batch of iron cores was produced (1L, 58.4 grams of FeCl 3 » 6H 2 0 and 21.5 grams of FeCl 2 » 4H 2 0).
- ferro fluid 67.6 mg was used for the production of coated magnetic particles. After the reaction with 10% carboxyethylsilanetriol sodium salt, the particles were washed in water and kept in bead storage buffer. Analyzed iron concentration using ICP measured 3.342 mg/ml. Zeta potential was measured to make sure that all the magnetic particles were properly coated. See Figure 25.
- the basic concepts of the present invention may be embodied in a variety of ways.
- the invention involves numerous and varied embodiments using sex sorted sperm to increase the genetic progress of a line, including, but not limited to, the best mode of the invention.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462088425P | 2014-12-05 | 2014-12-05 | |
PCT/US2015/064098 WO2016090310A1 (en) | 2014-12-05 | 2015-12-04 | Cell processing using magnetic particles |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3227661A1 true EP3227661A1 (en) | 2017-10-11 |
EP3227661A4 EP3227661A4 (en) | 2019-01-09 |
Family
ID=56092563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15866159.5A Withdrawn EP3227661A4 (en) | 2014-12-05 | 2015-12-04 | Cell processing using magnetic particles |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3227661A4 (en) |
AU (1) | AU2015357516A1 (en) |
WO (1) | WO2016090310A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3843544A1 (en) * | 2018-08-28 | 2021-07-07 | Boston Scientific Scimed Inc. | Systems and methods for thawing cells using magnetic particles |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789155A (en) | 1987-10-30 | 1998-08-04 | California Institute Of Technology | Process for identifying nucleic acids and triple helices formed thereby |
ES2091823T3 (en) | 1989-05-10 | 1996-11-16 | Us Agriculture | METHOD TO PRESELECT THE SEX OF THE PROGENIE. |
US6090947A (en) | 1996-02-26 | 2000-07-18 | California Institute Of Technology | Method for the synthesis of pyrrole and imidazole carboxamides on a solid support |
US6143901A (en) | 1996-07-31 | 2000-11-07 | Genesoft, Inc. | Complex formation between dsDNA and pyrrole imidazole polyamides |
US5998140A (en) | 1996-07-31 | 1999-12-07 | The Scripps Research Institute | Complex formation between dsDNA and oligomer of cyclic heterocycles |
JP2968231B2 (en) | 1997-04-11 | 1999-10-25 | 株式会社荏原製作所 | Air conditioning system |
US5985216A (en) | 1997-07-24 | 1999-11-16 | The United States Of America, As Represented By The Secretary Of Agriculture | Flow cytometry nozzle for high efficiency cell sorting |
US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6149867A (en) | 1997-12-31 | 2000-11-21 | Xy, Inc. | Sheath fluids and collection systems for sex-specific cytometer sorting of sperm |
US6071689A (en) | 1997-12-31 | 2000-06-06 | Xy, Inc. | System for improving yield of sexed embryos in mammals |
US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
US6472153B1 (en) | 1999-10-26 | 2002-10-29 | Epoch Biosciences, Inc. | Hybridization-triggered fluorescent detection of nucleic acids |
AU1778701A (en) * | 1999-11-17 | 2001-05-30 | University Of Virginia Patent Foundation | Sperm cell selection system |
US7208265B1 (en) | 1999-11-24 | 2007-04-24 | Xy, Inc. | Method of cryopreserving selected sperm cells |
US6263745B1 (en) | 1999-12-03 | 2001-07-24 | Xy, Inc. | Flow cytometer nozzle and flow cytometer sample handling methods |
AU1980202A (en) | 2000-11-22 | 2002-06-03 | Pharmacia Corporation | Methods and apparatus for producing gender enriched sperm |
US6576291B2 (en) | 2000-12-08 | 2003-06-10 | Massachusetts Institute Of Technology | Preparation of nanocrystallites |
US6416190B1 (en) | 2001-04-27 | 2002-07-09 | University Of Chicago | Apparatus for using optical tweezers to manipulate materials |
US6849394B2 (en) | 2002-02-21 | 2005-02-01 | Minitube Of America | Compositions comprising reproductive cell media and methods for using such compositions |
CN1774623B (en) | 2002-07-31 | 2012-02-01 | 阿尔利克斯公司 | System and method of sorting materials using holographic laser steering |
AU2003265362B2 (en) * | 2002-08-01 | 2009-11-05 | Xy, Llc. | Low pressure sperm cell separation system |
DE602004024874D1 (en) | 2003-03-28 | 2010-02-11 | Inguran Llc | EASTER-ASSORTED TIERSPERMIES |
NZ530972A (en) | 2004-02-05 | 2005-04-29 | Embrionics Ltd | A method and apparatus for orientating and selecting cells |
WO2012161764A1 (en) * | 2011-02-16 | 2012-11-29 | Fox Daniel N | Magnetic sorting of mammalian sperm having damaged membranes |
NZ705665A (en) * | 2012-08-29 | 2017-08-25 | Inguran Llc | Magnetic removal or identification of damaged or compromised cells or cellular structures |
US9757726B2 (en) * | 2013-03-14 | 2017-09-12 | Inguran, Llc | System for high throughput sperm sorting |
-
2015
- 2015-12-04 WO PCT/US2015/064098 patent/WO2016090310A1/en active Application Filing
- 2015-12-04 AU AU2015357516A patent/AU2015357516A1/en not_active Abandoned
- 2015-12-04 EP EP15866159.5A patent/EP3227661A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3227661A4 (en) | 2019-01-09 |
WO2016090310A1 (en) | 2016-06-09 |
AU2015357516A1 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11630108B2 (en) | Cell processing using magnetic particles | |
AU2019200730B2 (en) | Compositions and methods for improving the quality of processed sperm | |
EP2269617B1 (en) | Process for enriching a population of sperm cells | |
US10226041B2 (en) | Compositions and methods for improving the quality of processed sperm | |
US20230097054A1 (en) | Low sugar sperm media and compositions | |
WO2016090310A1 (en) | Cell processing using magnetic particles | |
AU2013202649B2 (en) | Compositions and methods for improving the quality of processed sperm | |
NZ712027B2 (en) | Compositions and methods for improving the quality of processed sperm | |
NZ617706B2 (en) | Compositions and methods for improving the quality of processed sperm | |
NZ725104B2 (en) | Compositions and methods for improving the quality of processed sperm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170626 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20181212 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 1/40 20060101ALI20181206BHEP Ipc: G01N 35/00 20060101ALI20181206BHEP Ipc: A01N 1/02 20060101ALI20181206BHEP Ipc: G01N 1/34 20060101ALI20181206BHEP Ipc: G01N 15/10 20060101ALI20181206BHEP Ipc: G01N 15/14 20060101ALI20181206BHEP Ipc: G01N 33/543 20060101ALI20181206BHEP Ipc: G01N 15/00 20060101AFI20181206BHEP Ipc: G01N 33/50 20060101ALI20181206BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220307 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230513 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230503 |